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ABSTRACT 
Evaluation of a Guided Decision Aid for Treatment Selection in  
Follicular non-Hodgkins Lymphoma 
 
Angela J. Lowery 
 
Decision aids for treatment selection have improved the decision-making process by increasing 
patient knowledge, decreasing decisional conflict (or uncertainty), increasing strength of 
preference for an option, and increasing decision satisfaction. Decision aids provide information 
and assist patients in making informed medical decisions. Guided decision aids help patients 
weigh pros and cons of options. This study involved the creation and evaluation of a guided 
decision aid for patients with follicular lymphoma, a disease with multiple complex treatment 
options. The aid was evaluated in a non-patient sample (30 males and 30 females, aged 40 to 79). 
Participants received either the guided decision aid or a comparison decision aid. Participants 
were asked to make a decision as if they were patients with follicular lymphoma by rating 
preference for each option and rank ordering treatment options before and after reading the 
materials. Decision satisfaction, decisional conflict, and knowledge of follicular lymphoma were 
assessed before and after reading the materials. Both groups showed a comparable increase in 
decision satisfaction, decrease in decisional conflict, and increase in knowledge after reading the 
materials. Thus, the decision aid was effective in improving the decision-making process. Both 
groups showed a change in preference for treatment options when rating treatment preference; 
however, only the comparison group showed a change in treatment preference when treatments 
were rank-ordered. Preference increased for watch and wait and biologic therapy and decreased 
for stem cell transplantation. The extent to which age, education, gender, depression, anxiety, 
need for cognition, and monitory/blunting predicted variability in satisfaction with decision and 
decisional conflict was examined. There were no significant predictors of residualized change in 
decision satisfaction; however, age significantly predicted residualized change in decisional 
conflict, and younger participants showed a decrease in decisional conflict. Analysis of the 
extent to which reading time and decision-making time predicted residualized change in 
knowledge suggested that longer reading times showed an increase in knowledge. These findings 
suggest that receiving information about follicular lymphoma effectively improved the decision-
making process for a non-patient sample regardless of whether treatment preference changed. 
Additionally, the findings suggest that the guided decision aid may be more effective for younger 
ages.  
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Evaluation of a Guided Decision Aid for Treatment Selection in Follicular non-Hodgkins 
Lymphoma 
Cancer accounts for 22.8% of all deaths. Out of all deaths, it is the second leading cause of 
death following heart disease (National Center for Health Statistics, 2004). Of the types of 
cancer, lung cancer is currently the leading cause of death in both men and women. Breast cancer 
is currently the most prevalent cancer in women, and prostate cancer is currently the most 
prevalent cancer in men. Lymphomas (cancers of the lymphatic system) are currently the fifth 
leading cancer in new cancer cases and the seventh leading cause of cancer-related death. There 
are two primary types of lymphoma: Hodgkins lymphoma and non-Hodgkins lymphoma 
(NHL). Of the lymphomas, NHL is the most prevalent (American Cancer Society, 2005). 
NHL was estimated to account for 56,390 new cancer cases in 2005 and 19,200 deaths 
(American Cancer Society, 2005). The incidence rate of NHL has doubled since the 1970s. Some 
symptoms of NHL include fatigue, weight loss, enlarged lymph nodes, itching, night sweats, and 
fever. Types of NHL can be classified several ways including by stage of the disease (how far 
the disease has spread from the original site), speed of growth [indolent (slow-growing) versus 
aggressive (fast growing)], and location [contiguous (affected sites close together) versus non-
contiguous (affected sites far apart)]. The most common type of NHL is diffuse large B-cell 
lymphoma (an aggressive disease), and the second most common is follicular (an indolent 
disease) (National Cancer Institute, 2005). Treatment for aggressive lymphomas typically 
involves more aggressive treatment measures with the goal of bringing the disease to remission. 
However, treatment of indolent lymphomas is more controversial. Patients are often faced with 
the decision of when to begin treatment of the disease, what type of treatment to use, when and if 
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to begin more aggressive treatment measures, and what treatment to choose when the disease 
recurs (Ansell & Armitage, 2005).  
Treatment Decisions in Cancer 
 Patients with cancer often experience difficult decisions in selecting among treatment 
options. For example, patients with stage II prostate cancer can face several treatment options 
including surgical removal of the prostate (prostatectomy), watchful waiting, external radiation, 
or brachytherapy (radiation near the site of the tumor) (Holmes-Rovner et al., 2005). Patients 
with breast cancer who have had a mastectomy can face the decision of whether to receive 
additional chemotherapy (Peele et al., 2005).  
Patients with follicular lymphoma may be treated with radiation, biologic therapy, 
combination chemotherapy, watch and wait, or a variety of clinical trials. When the disease 
relapses, patients have other treatment options from which to choose including bone marrow 
transplantation (Ansell & Armitage, 2005). Chemotherapy is a treatment in which a drug is 
transfused into the veins, often when the patient is first diagnosed (Gandhi & Marcus, 2005). 
This treatment is often well-tolerated in patients. There are several side effects including nausea, 
hair loss, fatigue, and mouth sores. Drugs are available to help ease side effects such as nausea 
(Leukemia & Lymphoma Society, 2006). Radiation therapy uses high-energy rays to target 
cancer cells (Leukemia & Lymphoma Society, 2006). Side effects include fatigue, decreased 
appetite, skin irritation, and bone marrow suppression; however, these side effects are often short 
in duration (Holman et al., 2004). Biologic therapy uses antibodies to target the cancer cells 
directly while leaving other cells alone (American Cancer Society, 2006). This treatment is 
associated with side effects such as fever, chills, nausea, and headache; however, these are 
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usually most prominent only during the initial treatment with the drug (Holman et al., 2004). 
Bone marrow stem cell transplantation is another option for some patients in which high-dose 
chemotherapy is given to the patient, which destroys much of the bone marrow. Bone marrow 
stem cells from a donor are then transfused into the blood (Cancer Facts, 2006). Stem cell 
transplantation offers a relatively safe way to deliver high dose chemotherapy and it can offer a 
potential cure for lymphoma. However, it is potentially associated with very serious risks. 
Patients can have a suppressed immune system for a long time, and some patients may develop 
graft versus host disease, a potentially fatal condition in which the body rejects the donor cells 
(Holman et al., 2004). Some patients may also explore clinical trials as a treatment option, which 
are research studies in which new treatment options are being tested. Patients may have access to 
some highly effective treatments through these studies; however, patients may not have a choice 
as to which treatment they will receive (Cancer Facts, 2006). Finally, since follicular lymphoma 
is a slow-growing cancer, patients may also have the choice of watching and waiting until 
symptoms of the disease become more prominent, without necessarily shortening their survival 
time. Patients would not need to worry about side effects since they are not actively being 
treated; however, they will require fairly frequent scans, medical tests, and examinations of the 
lymph nodes (Holman et al., 2004).  
For follicular lymphoma patients, the treatment decision is difficult partly because of the 
number of treatment options from which patients must choose (Ansell & Armitage, 2005). 
Additionally, the decision can be difficult because patients are often faced with the choice of 
when and if to begin more aggressive treatment. When the disease recurs, patients may also be 
faced with a difficult choice because treatments used before may not work as well again. As 
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discussed in the last paragraph, the choice of whether to begin treatment may also be difficult 
because the treatment may not necessarily lengthen the survival time (Holman et al., 2004). 
Several factors have been associated with cancer decision making that can make the decision 
process more difficult. These include a lack of knowledge of treatment options (Schapira et al., 
1997) and decisional conflict, which is uncertainty about which option to choose (OConnor, 
1995). Other factors associated with decreased effectiveness in decision making include higher 
anxiety, inability to receive information, poor health, and fatigue (Saino et al., 2001). 
Utility of Decision Aids in Cancer 
 There is no one accepted definition of a decision aid. For the purpose of this study, 
decision aid will be defined as any source of information such as pamphlets, audiotapes, 
counseling sessions, or videos that are designed to offer information to patients about medical 
disease and/or medical dilemmas to help patients make a medical decision. A guided decision aid 
will be defined as a source of information such as a pamphlet, audiotape, or video that not only 
offers information about medical disease and medical dilemmas, but offers exercises to help 
patients identify their values and deliberate between options according to their values. Guided 
decision aids are designed to educate patients about medical disorders and options and to assist 
in making informed, satisfactory decision that are consistent with their values. 
 Several decision aids have been created to increase patient knowledge about treatment 
options (Whelan et al., 2001; Whelan et al., 2004), decrease decisional conflict associated with 
the decision making process (Fiset et al., 2000; Whelan et al., 2004), increase the strength of 
preference for an option (Brundage et al., 2000), and increase satisfaction with the decision 
making process (Brundage et al., 2000; Molenaar et al., 2001; Onel et al., 1998; Sepucha et al., 
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2000). The use of decision aids in selection of treatment for cancer is a fairly new area of 
research. These aids have been evaluated in breast cancer, prostate cancer, non-small cell lung 
cancer, ovarian cancer, and chronic myeloid leukemia. Other aids have been created (e.g., 
decision aids for leukemias), but have not been empirically evaluated.  
There are several formats that have been used to relay treatment information to patients and 
to help guide the decision process. For example, decision boards have been created that typically 
utilize a large, blank foam board. Patients are read informational cards by the provider, and the 
cards are attached to the board with Velcro after they have been read (e.g., Whelan et al., 2004). 
Decision counseling or interviewing can also be used to help patients make a decision and to 
generate factors that are important in the decision making process (e.g., Feldman-Stewart et al., 
2001; Sepucha et al., 2000). Other methods that have been used to relay information to patients 
include videotapes (e.g., Schapira et al., 1997), computer software (e.g., Molenaar et al., 2001), 
booklets (e.g., Fiset et al., 2000), and audiotapes (e.g., Goel et al., 2001). 
 Several strategies have been used to evaluate decision aids for cancer. Aids have been 
evaluated as to whether they help patients increase knowledge about the disease and treatment 
options (e.g., Brundage et al., 2000), decrease decisional conflict (e.g., Fiset et al., 2000), 
increase decision satisfaction (Whelan et al., 2003), influence quality of life (e.g., Molenaar et 
al., 2001), and whether they are acceptable (e.g., Levin et al., 1992). Several methods have been 
used to evaluate these aids including comparing the aids to a standard-of-care control group (e.g., 
Whelan et al., 2004) or comparing different media formats of the decision aid (e.g., Street et al., 
1995). Some studies also have used pre-post measures of the constructs described above (e.g., 
Chapman et al., 1995). Most of the studies that will be described used patients as participants; 
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however, some studies used non-patients who made decisions about treatment as if they were 
patients. The principle purpose of this dissertation was to develop and evaluate a guided decision 
aid for patients with indolent follicular lymphoma. 
Review of the Literature 
 The following section is an overview of current decision aids for treatment selection in 
cancer that have been utilized and evaluated.  The aids are organized according to the type of 
cancer including breast cancer, prostate cancer, non-small cell lung cancer, ovarian cancer, and 
chronic myeloid leukemia. Several methodological criticisms are then offered. 
Decision Aids in Breast Cancer 
Several studies have examined the use of a decision aid in considering mastectomy 
versus lumpectomy treatments for breast cancer. Sepucha et al. (2000) conducted a pilot study to 
examine whether recording of a decision counseling session would increase satisfaction with the 
consultation and would increase the quality of the treatment decision in 24 patients with early-
stage breast cancer. The counseling sessions included a 5-step agenda to prompt patients to 
provide reasoning for their views. Patient input was not used in the development of the agenda. 
Decision quality was measured using the Decision Quality Scale, which includes 10 Likert-type 
items (Howard, 1989). The authors stated that decision quality is based on "six elements;" 
however, these elements are not identified or defined (Sepucha et al., 2001, p. 1232). The authors 
found that the counseling group and the standard-of-care control group significantly increased 
the quality of the decision; however, the counseling group reported significantly higher decision 
quality. Molenaar et al. (2001) evaluated the extent that an interactive CDROM would impact the 
treatment decision, quality of life, and patient satisfaction in 180 breast cancer patients. A breast 
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cancer support group and medical team were involved in the creation of the CDROM. The 
researchers found that there was no difference between the CDROM group and the standard-of-
care control group in the actual decision choice; however, the CDROM group was more satisfied 
with the decision. The CDROM group also had better quality of life directly following the 
decision aid, three months later, and nine months later. However, patients were allowed to 
choose which group in which they wanted to participate; thus, there may have been other 
characteristics that influenced the quality of life ratings. Street et al. (1995) compared the effects 
of a computer program to that of a brochure using 60 breast cancer patients. No patients were 
involved in the development of the computer program. The authors hypothesized that those using 
the computer program would learn more about breast cancer treatment, express more optimism 
about the future, and be more involved in decision making as compared to the brochure group. 
They found that overall knowledge about breast cancer treatment increased in both groups, but 
there was no significant difference between the two groups in the amount of knowledge gained. 
In addition, there was no difference between the groups on the amount of optimism expressed or 
the involvement in the decision. The authors also found that younger and more educated 
individuals were more involved in the decision-making process. However, the authors did not 
report findings of whether age or education influenced optimism or knowledge. 
Other formats used in mastectomy/lumpectomy decisions have included audiotapes, 
videotapes, and decision boards. Goel et al. (2001) compared the effects of an audiotape/booklet 
decision aid to that of a pamphlet using 140 breast cancer patients. Both media contained the 
same information; however, only the audiotape/booklet contained photographs and values-
clarification exercises. Only one patient was involved in the creation of the audiotape/booklet. 
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The authors hypothesized that use of the decision aid would decrease decisional conflict and 
increase breast cancer knowledge as compared to the pamphlet group. There was no significant 
difference found between the two groups. This study gathered some information about patient 
characteristics such as anxiety and employment status. The authors reported that a trend was 
evident in that those who preferred mastectomy or were undecided showed more of a decrease in 
decisional conflict after using the decision aid than those who preferred lumpectomy. A concern 
with this study was that multiple t-tests were conducted without adjusting alpha to control for 
family-wise Type I error. Chapman et al. (1995) examined whether 48 psychology and 34 
nursing undergraduates who viewed a video decision aid would have more knowledge about 
breast cancer and different treatment preferences than those who used a booklet. The 
development of the decision aid video was not described. The authors found that for psychology 
undergraduates, the video decision aid group gained more knowledge as compared to the booklet 
group. For nursing students, there was no difference in knowledge between the video and the 
booklet groups. The authors did not assess knowledge of breast cancer before groups were given 
the materials; thus, it is unclear whether prior knowledge may have influenced the results. For 
both nursing and psychology undergraduates, the video groups showed greater preference than 
the booklet groups for lumpectomy. This study did not examine whether individual 
characteristics may have influenced decision-making. Whelan et al. (2004) compared the effects 
of a decision board decision aid to that of regular physician consult in 201 breast cancer patients. 
This decision board was made out of 20x26 inch foam core. Panels of information were covered 
by sliding doors, and the panels were revealed to the patient in sequence. It was not clear 
whether patients offered input into the creation of the board. The decision board group showed 
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higher knowledge of breast cancer treatment, lower decision conflict, and more decision 
satisfaction than the control group. However, the authors did not measure baseline scores of 
knowledge, decision conflict, and decision satisfaction, so it is unclear whether these groups may 
have differed prior to using the decision board.  
Decision aids also have been developed to help patients make decisions related to 
adjuvant therapy, which is chemotherapy used in conjunction with breast removal surgery. 
Several decision boards have been created for this purpose. Whelan et al. (2003) and Levine et 
al. (1992) evaluated a decision board to help patients decide whether to use chemotherapy. 
Levine et al. (1992) examined the test-retest reliability and acceptability of the decision aid in 13 
healthy volunteers, and acceptability in 37 breast cancer patients. The design of this board 
required a physician to read cards with information aloud to the patient. The patient then attached 
each card to the board after it was read. When finished, all information was on the board in front 
of the patient. The authors reported that this decision aid was piloted in a group of 6 patients to 
assess clarity and determine whether the information was related to the patients prior 
experience; however, it was not clear how this was done. The authors found that in healthy 
adults, treatment preferences remained stable over a two week time period, indicating reliability 
of the aid. The 37 breast cancer patients reported that the aid was understandable and helped 
them make decisions; however, these results were not statistically analyzed and there was no 
control group for comparison. Individual patient characteristics were not examined to determine 
if they influenced the effectiveness of the decision aid. Whelan et al. (2003) studied whether the 
use of a decision board aid would increase knowledge and decision satisfaction when compared 
to a control group. The decision board was similar to the board described before in which cards 
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were read to the patient and then attached to the board. The authors did not discuss how the 
decision aid was developed. There were 176 breast cancer patients included in the study. The 
authors found that patients utilizing the decision board showed more knowledge and made more 
satisfactory decisions than patients who only received a medical consultation. However, 
knowledge and satisfaction were not assessed before the use of the decision board, so it was not 
clear whether these improved. Anxiety decreased equally for both groups. Whelan et al. (1995) 
created a similar decision board to help patients decide whether to use radiation therapy and 
compared this board to a regular physician consultation. A group of experts designed the aid. 
This decision board was initially shown to 10 healthy women and 16 patients to assess whether 
the information was clear and non-threatening. When they tested the aid using 82 patients, they 
found that the decision board group resulted in greater knowledge on a 10-item true/false quiz 
than the control group on only one question (i.e., that radiation could not be repeated in the same 
breast); however, the decision board group felt that they were offered more of a choice in the 
decision than the control group. Participant characteristics were not evaluated as predictors of 
effectiveness of the aid. Finally, Irwin et al. (1999) created a decision board to help increase 
patient comprehension of two chemotherapy regimens in 46 patients. Initially, 4 patients and 7 
healthy women were given the aid to verify clarity. No description was offered as to how the aid 
was developed. The two treatment options were presented to 46 patients in two different orders. 
After the decision aid was administered, patients showed adequate knowledge of the treatment 
options. There was no difference in knowledge found between which treatment option was 
shown first. Knowledge was not assessed prior to the administration of the aid; thus, the initial 
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level of knowledge was not clear. The authors asked women why they made their respective 
treatment choices. Most women listed side effects or treatment schedules as reasons. 
Decision Aids in Prostate Cancer 
 Several studies have examined decision aids in choosing prostatectomy surgery, 
radiation, or watchful waiting as treatments for prostate cancer. Onel et al. (1998) hypothesized 
that patients knowledge of prostate cancer would increase following an informational tape in a 
group of 97 prostate cancer patients. They did not describe how this decision aid was developed. 
The authors found that that the subjective reports of knowledge about prostate cancer increased 
after viewing the video; however, no statistics were used to determine the significance of this 
increase. Additionally, there was no control group for comparison. The authors did not examine 
personal characteristics as predictors of increase in knowledge. Schapira et al. (1997) also 
examined the effects of an information video. Thirty-two men without prostate cancer viewed an 
informational video about prostate cancer and treatment options. Oncologists were involved in 
the creation of the decision aid. Patient focus groups were also used to determine topics for the 
decision aid that would be relevant to patients. The results showed that knowledge increased 
after viewing the videotape; however, there was no control group for comparison. Participant 
characteristics were not examined as predictors of the increase in knowledge. 
 Other studies have used an interview format as a decision aid for prostatectomy surgery, 
radiation, or watchful waiting. Feldman-Stewart et al. (2001) hypothesized that after using an 
interview decision aid, 69 participants never diagnosed with prostate cancer would identify 
attributes important in treatment selection and would identify preferred treatment options. They 
described the decision aid, but did not describe the method used in creating it. The authors found 
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that the participants were successful at identifying several attributes that were important to them 
in making a treatment decision and changed treatment preference while using the aid. The 
authors stated that they found that there were no participant personal characteristics associated 
with the findings; however, the authors did not clearly identify the characteristics that were 
analyzed. The authors did not assess the patients prior to use of the aid and did not use a control 
group for comparison. Davidson and Degner (1997) hypothesized that the use of an interview in 
decision making would decrease anxiety and depression in 60 men newly diagnosed with 
prostate cancer. The authors did not describe how this decision aid was developed. A control 
group of patients was given a pamphlet with comparable information. Neither the use of the 
decision aid nor the control pamphlet decreased anxiety or depression; however, in the decision 
aid group, patients reported that a list of questions to ask a physician was helpful in 
communicating with the physician. Anxiety and depression were not assessed as predictors of 
effectiveness of the decision aid. 
 One study used multiple media to create decision aids for choosing prostatectomy 
surgery, radiation, or watchful waiting. Holmes-Rovner et al. (2005) compared different media 
formats of a decision aid including an audiotape, a booklet, and the internet. In creating the 
decision aid, men with prostate cancer were interviewed to determine information important to 
include. Then, the aid was shown to a focus group to determine whether the information was 
confusing. The authors examined whether knowledge of prostate cancer differed among 60 men 
with prostate cancer using each of the three types of aids. No significant difference in knowledge 
was found between the groups. Those who used the audiotape were much less likely to share the 
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decision aid with their family. No individual characteristics were examined as predictors of 
effectiveness of the aid. 
Decision Aids in Lung Cancer 
 Two studies have examined decision aids for the choice between radiation alone or a 
combination of chemotherapy and radiation in the treatment of non-small cell lung cancer. 
Brundage et al. (2001) hypothesized that an interview decision aid would increase patient 
knowledge, strengthen treatment preference, and decrease decisional conflict in a group of 27 
patients. The authors did not describe how the decision aid was developed. The aid increased 
knowledge and decreased decisional conflict. Treatment preference was strengthened only for 
those that did not have a strong preference before the use of the aid. No control group was used 
for comparison. Brundage et al. (2000) created a decision board, which was a large board that 
described treatment choices for lung cancer and offered exercises to aid in treatment choice. The 
authors did not describe how the decision aid was created. The decision aid was given to a group 
of 18 patients with lung cancer. Although no hypotheses were stated, the results of the study 
indicated that use of the aid increased patient knowledge of lung cancer, increased the strength of 
treatment preference, and decreased decision uncertainty. No control group was used for 
comparison of these findings. The authors reported patient demographics, but did not examine 
participant characteristics that influenced effectiveness of the decision aid. Fiset et al. (2000) 
created a booklet/audiotape decision aid for deciding among radiation, chemotherapy, and 
supportive care. Oncologist experts were involved in the creation of the decision aid. The aid 
was then evaluated by 6 patients for content validity and acceptability. The aid was then given to 
20 lung cancer patients. This combination of booklet and audiotape aid was expected to decrease 
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decisional conflict and decrease decision uncertainty. The results of the study supported these 
hypotheses. The authors also found a greater change in preference for treatment choice in those 
who were more undecided before using the decision aid. There was no control group used to 
compare the performance of the intervention group. 
Decision Aids in Ovarian Cancer 
 Elit et al. (1996) created a decision board to help patients decide between chemotherapy 
options for advanced ovarian cancer. Similar to other decision boards, an oncologist read 
informational cards aloud to patients and then attached them to the board. In creation of the 
decision aid, the authors stated they observed patient interactions with oncologists and surveyed 
oncologists to determine important content. However, patients were not directly involved in the 
development of the decision aid. The decision board was used with 37 healthy women and 11 
ovarian cancer patients. The authors stated that their goal was to examine the feasibility, 
comprehension, reliability, and validity of the aid. The authors reported that the validity of the 
aid was supported in that the patients treatment choices were affected by the information offered 
on survival. The authors reported that interobserver reliability of the aid was supported in that 
two different observers achieved 100% agreement. The authors stated that these observers were 
observing choice, but they were not clear in describing exactly what this meant. Scores on 
measures of anxiety did not change during administration of the aid. Participant characteristics 
were not examined as predictors of effectiveness of the aid. 
Decision Aids in Leukemia 
 Only one published study (Sebban et al., 1995) has examined the effectiveness of a 
decision aid in the treatment of a blood cancer. A decision board aid was developed to help 
 15
patients with chronic myeloid leukemia choose between a bone marrow transplant and additional 
chemotherapy. The authors did not describe how the decision aid was developed. This aid was 
administered to 42 non-patients. The authors reported that they attempted to demonstrate 
construct validity of the aid in several ways. These included demonstration that manipulations of 
survival probabilities would create predictable changes in treatment choices (testing 
understanding of information as a determinant of choice), that choices in the decision aid group 
would differ from choices in the group that used a shorter version of the aid (testing impact of 
quantity of information on choice), that older individuals would make more conservative 
choices, and that participants would be more satisfied with their decisions in the decision aid 
group. All hypotheses were supported except that older individuals did not make more 
conservative treatment choices. Since the topic of this study is relevant to the current project, this 
study is described further in the Statement of the Problem section. 
Methodological Critique 
There are several methodological shortcomings in the research literature on decision aids 
for selection of cancer treatment. Several studies failed to describe the method used to create the 
decision aid (Brundage et al., 2001; Chapman et al., 1995; Sepucha et al., 2000; Street et al., 
1995). This presents a problem in that it precludes replication and an examination of adequacy of 
content. Other studies did not utilize patient input in determining the content of the decision aid 
(Brundage et al., 2000; Davidson & Degner, 1997; Elit et al., 1996; Feldman-Stewart et al., 
2001; Levine et al., 1992; Molenaar et al., 2004; Onel et al., 1998; Whelan et al., 1995; Whelan 
et al., 2003). This presents a problem in that the authors may have missed content that could have 
been useful for patients who were attempting to make a treatment selection. There were also 
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several studies that did not examine participant characteristics that may have influenced the 
effectiveness of the decision aid (Brundage et al., 2000; Brundage et al., 2001; Elit et al., 1996; 
Fiset et al., 2000; Holmes-Rovner et al., 2005; Onel et al., 1998; Schapira et al., 1997; Sebban et 
al., 1995). This presents a problem in this literature because participant characteristics may help 
determine for whom the aid would be most useful, and may also help in modifying the aids to 
benefit all types of patients. Finally, several studies failed to use a control group as a comparison, 
which precludes examination of whether the effects of the decision aid differ from or was  
superior to the effects of the regular standard-of-care (Elit et al., 1996; Feldman-Stewart et al., 
2001; Holmes-Rovner et al., 2005; Irwin et al., 1999; Levine et al., 1992; Onel et al., 1998; 
Schapira et al., 1997). 
Statement of the problem 
Patients with cancer often experience difficult decisions in selecting among treatment 
options. For example, patients with breast cancer who have had a mastectomy can face the 
decision of whether to receive additional chemotherapy (Peele et al., 2005). Several factors have 
been associated with cancer decision making such as knowledge of treatment options (Shapira et 
al., 1997) and decisional conflict (i.e., uncertainty about which option to choose; OConnor, 
1995). Other factors associated with decreased effectiveness in participation in decision making 
include higher anxiety, inability to receive information, poor health, and fatigue (Saino et al., 
2001). 
Decision aids in cancer treatment selection have improved the decision making process 
by increasing patient knowledge about treatment options (e.g., Brundage et al., 2000; Brundage 
et al., 2001), decreasing decisional conflict associated with the decision making process (e.g., 
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Brundage et al., 2000; Fiset et al., 2000), increasing the strength of preference for an option (e.g., 
Brundage et al., 2001), and increasing satisfaction with the decision making process (e.g., 
Brundage et al., 2000; Molenaar et al., 2001; Onel et al., 1998; Sepucha et al., 2000). However, 
as discussed previously , flaws were evident in several of these studies. Several studies failed to 
describe the method used to create the decision aid (e.g., Brundage et al., 2001; Sepucha et al., 
2000), failed to utilize patient input in determining the content of the decision aid (e.g., Brundage 
et al., 2000; Molenaar et al., 2004; Onel et al., 1998), failed to examine participant characteristics 
that may have influenced the effectiveness of the decision aid (e.g., Brundage et al., 2000; 
Brundage et al., 2001; Onel et al., 1998), and failed to use comparison group (e.g., Onel et al., 
1998). Thus, the results that support these decision aids are open to question. 
Only one published study (Sebban et al., 1995) has examined the effectiveness of a 
decision aid in the treatment of a blood cancer. A decision board aid was developed to help 
patients with chronic myeloid leukemia choose between a bone marrow transplant and additional 
chemotherapy. The aid described scenarios of how BMT and chemotherapy were performed. 
Potential quality of life during each treatment and potential outcome of each treatment (i.e., 
morbidity and mortality) were also described. Forty-two participants (ranging in age from 23 to 
61 years) that had never been diagnosed with leukemia were included in the evaluation of the 
aid. Participants were randomly assigned to a decision board group or a group that was given a 
shorter version of the information that had been offered in the decision aid. The latter group was 
considered a control group. A foam board was used to present the scenario cards. The cards were 
attached to the board once they were read by the patient. The first hypothesis was that 
manipulations of survival probabilities would create predictable changes in treatment choices 
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(testing understanding of information as a determinant of choice). This first hypothesis was 
examined in 16 of the participants; however, the authors failed to state their reasoning for using a 
smaller portion of their sample. The second hypothesis was that choices in the decision aid group 
would differ from choices in the group that used the shorter version (testing impact of quantity of 
information on choice). This hypothesis was supported. The third hypothesis, that older 
individuals would make more conservative choices, was not supported. The final hypothesis, that 
participants would be more satisfied with their decisions in the decision aid group, was 
supported.  
It is unfortunate that there is only one published aid that has been evaluated for use in a blood 
cancer, as there are other blood cancers that involve difficult treatment decisions. The present 
study involved the creation of a guided decision aid for patients with follicular lymphoma. 
Follicular non-Hodgkins lymphoma was previously discussed as a disease with multiple 
complex treatment options from which patients must choose (Ansell & Armitage, 2005). Patients 
often must make the decision of when to begin aggressive treatment and these patients must 
often choose among several options including radiation, biologic therapy, combination 
chemotherapy, watch and wait, or a variety of clinical trials. However, an empirically validated 
aid has not yet been created for this disorder. The purpose of this study was to create a guided 
decision aid for follicular NHL using the Ottawa Decision Support Framework (OConnor et al., 
1998). The format of this framework includes offering information about the disease, 
information about treatment options, and providing a method for patients to weigh options 
according to their specific values. Decision aids that have employed this framework have been 
empirically supported in several areas of medical decision making, including autologous blood 
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donation before surgery (Grant et al., 2001), discontinuation of cardiac arrest resuscitation (van 
Walraven et al., 2001), antithrombotic therapy for patients with atrial fibrillation (Man-Son-Hing 
et al., 2000), breast cancer prevention (Stacey et al., 2002), intubation in chronic obstructive 
pulmonary disease (Wilson et al., 2005), tube feeding (Mitchell et al., 2001), and treatment of 
lung cancer (Fiset et al., 2000). These aids have been empirically supported in that they have 
been shown to decrease decisional conflict, increase satisfaction with decision, and increase 
knowledge. Not only have decision aids created using this framework been empirically 
supported, this framework is also unique in that it describes a detailed method for creating a 
decision aid that will be useful to patients. The framework encourages the inclusion of experts 
and patients in the creation of the decision aid to ensure that the information will be accurate and 
relevant to patient needs. Additionally, this framework encourages patients to examine the 
available options according to their own values, which ensures that patients are making a choice 
that will be most suitable for them. Finally, the creators of the Ottawa Framework also evaluated 
the psychometric properties of measures used to evaluate the decision aid in terms of decision 
satisfaction and decisional conflict (Holmes-Rovner et al., 1996; OConnor et al., 1995). 
The goal of the present study was to develop and evaluate a guided decision aid for treatment 
selection in follicular lymphoma, which is the most common non-Hodgkins lymphoma that has 
the highest potential for conflict among treatment options. Information for the decision aid was 
collected from a literature review of current treatment options, input from lymphoma patients, 
and input from oncologists that specialize in hematological malignancies.  
The guided decision aid was evaluated in a non-patient sample, and participants were asked 
to make a decision about treatment as if they were a patient with NHL. Most of the studies 
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discussed earlier used patient samples to evaluate a decision aid. A few studies used non-patients 
with successful results. Chapman et al. (1995) found that psychology undergraduate students 
scored higher on measures of knowledge after watching a video than after reading a booklet; 
however, baseline knowledge was not assessed. Schapira et al. (1997) demonstrated that an aid 
increased knowledge of the disease and the treatment options, but did not utilize a comparison 
group. Feldman-Stewart et al. (2001) demonstrated that participants could identify attributes 
important to them after using the aid and treatment choice changed over the course of using the 
aid; however, there was no assessment at baseline and no comparison group was utilized. 
Additionally, the authors did not describe the method used in creating the decision aid. Elit et al. 
(1996) indicated that comprehension was high following use of the decision aid; however, 
baseline comprehension was not assessed and no statistics were utilized. Finally, Sebban et al. 
(1995) demonstrated that the treatment selection differed between groups that received a decision 
aid or a shortened version of the decision aid; however, the difference between the materials was 
not clear. There were several benefits to using a non-patient sample in this study. Since none of 
the patients in this study had been diagnosed with cancer, it omitted potential problems 
associated with any direct prior experience with cancer treatment. Additionally, since patients 
made decisions about treatment using a standard patient description, this allowed for control over 
the situation in which the decision was made. 
Participant characteristics that may influence the effectiveness of decision aids were also 
explored. These factors had been largely ignored in the literature. A few studies examined how 
personal characteristics affected the decision-making process. Street et al. (1995) found that 
younger and more educated individuals were more actively involved in the decision-making 
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process. Goel et al. (2001) and Brundage et al. (2001) found that those who were initially 
undecided had a greater increase in treatment preference after using a decision aid. Sebban et al. 
(1995) found that older adults were not more likely to make conservative treatment selections. 
Other studies examined how the decision aid affected personal characteristics. Whelan et al. 
(2003) found that patient anxiety decreased over the course of using a decision aid; while 
Davidson and Dengler (1997) and Elit et al. (1996) found that anxiety and depression did not 
decrease over the course of using a decision aid. However, none of the studies examined 
participant characteristics as a predictor of effectiveness of decision aids. 
Information about participant characteristics may be valuable in determining the 
characteristics of individuals for whom the aid would be most useful. This information also may 
be useful for modifying the proposed aid to maximize its effectiveness for the greatest number of 
potential users. The present study examined participant characteristics that could account for 
some of the variance in changes in ratings on decision satisfaction and decisional conflict. We 
were interested in the extent to which age, gender, education, trait anxiety, depression, 
monitoring/blunting, and need for cognition would be predictive of decision satisfaction and 
decisional conflict. Older patients prefer to receive less medical information and to take less of 
an active role in the decision-making process (Pinquart & Duberstein, 2004); thus, older 
individuals may be less satisfied and feel more uncertain about their decision. Those with higher 
education have tended to desire being more involved in the decision-making process (Funk, 
2004), and may be more satisfied and less conflicted with their decisions after using the decision 
aid. Anxiety and depression are common psychological responses to cancer diagnoses (Block, 
2006) that have been shown to have a negative effect on ones ability to participate effectively in 
 22
medical decisions (Saino et al., 2001; Thomas et al., 1999). Thus, it might be expected that those 
with higher anxiety and higher depression may experience less satisfaction and more decisional 
conflict than those with lower scores. Need for cognition is an individuals tendency to engage 
in and enjoy effortful cognitive endeavors (Cacioppo et al., 1984, p. 3). Individuals high in this 
characteristic may enjoy the acquisition of knowledge, the weighing of values, and the decision-
making process more than those who are low in need for cognition. Finally, styles of coping 
including blunting (preference for distraction from stressful information) and monitoring 
(preference for attending to stressful information) may also be related to the effectiveness of the 
aid in that those who have a higher preference for distraction from stressful information may 
experience less satisfaction and more decisional conflict following exposure to potentially 
stressful information in the decision aid. Additionally, since the decision aid offers information 
about follicular lymphoma and its treatment options along with exercises to help participants 
make a decision, those with a higher desire for cognitive activity (higher scores on the Need for 
Cognition Scale) and those with a higher preference for information relating to a stressful 
situation (higher scores on the Miller Behavioral Style Scale) were expected to experience 
greater decision satisfaction and lower decisional conflict as a result of using the decision aid, as 
these groups are more likely to have a positive experience in dealing with the information 
included in the aid. We also examined how reading time and the time spent making the decision 
influenced knowledge gained from the decision aid. It was thought that those who spent more 
time reading the materials and deliberating about the decision might gain more knowledge about 
follicular lymphoma. 
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As discussed previously, blood cancers have been largely ignored in the decision aid 
literature. The focus of this study was to create and evaluate a decision aid for treatment 
selection in follicular NHL, a disease with multiple complex treatment options. This study is 
unique in comparison to the discussed literature in several other respects. Many of the described 
studies opted to use either a pre/post design or compared results of an experimental to a control 
or comparison group. These approaches enable one to not only examine whether variables 
change after use of the decision aid, but also how this change compares to that of a comparison 
group. The current study utilized both approaches. For the comparison group, this study used a 
shortened version of the guided decision aid, which was labeled a comparison decision aid. To 
create this pamphlet, portions of the guided decision aid were removed that were unique to the 
Ottawa Framework (e.g., weighing of pros and cons). This made the comparison decision aid 
more similar to a standard brochure. As discussed previously, our use of a non-patient sample 
allowed us to control for several factors including prior experience with treatment and the 
situation in which the decision was made. This study is also unique in our use of patient input 
into the creation of the decision aid. Several studies either asked patients what to include or 
asked patients to evaluate the content of the aid. We chose to do both, which ensured that we 
were getting optimum patient contribution to the creation of the decision aid. Finally, for the 
reasons described above, we chose to evaluate participant characteristics as predictors of 
effectiveness of the decision aid. 
As discussed previously, decision aids in cancer treatment selection have improved the 
decision making process by increasing patient knowledge about treatment options (e.g., 
Brundage et al., 2000), decreasing decisional conflict (e.g., Brundage et al., 2000), increasing the 
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strength of preference for an option (e.g., Brundage et al., 2001), and increasing satisfaction with 
the decision (e.g., Brundage et al., 2000). However, results of some these studies arequestionable 
due to several flaws such as failing to describe the method used to create the decision aid (e.g., 
Brundage et al., 2001), failing to utilize patient input in content of the decision aid (e.g., 
Brundage et al., 2000), failing to examine participant characteristics that may have influenced the 
effectiveness of the decision aid (e.g., Brundage et al., 2000), and failing to use comparison 
group (e.g., Onel et al., 1998). Thus, the results that support these decision aids are open to 
question. Additionally, only one decision aid has been evaluated for treatment selection in a 
blood cancer (leukemia). The aim of the current study was to create and evaluate a guided 
decision aid for follicular NHL in a non-patient sample, while correcting for some common 
flaws in previous studies. 
Hypotheses 
Based upon the above discussion, the following hypotheses were examined in this study.  
1. Total scores on the satisfaction with decision scale would increase in the guided 
decision aid group following use of the aid, more than the comparison group scores 
would increase following use of the pamphlet. This was hypothesized because several 
studies have demonstrated that use of decision aids increased scores on measures of 
decision satisfaction (e.g., Sepucha et al., 2000; Whelan et al., 2003; Whelan et al., 
2004).  
2. The guided decision aid group scores would decrease on the decisional conflict scale 
following use of the aid, more than the comparison group scores would decrease 
following use of the pamphlet. This was hypothesized because several studies have 
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demonstrated that use of decision aids decreased scores on measures of decisional 
conflict (e.g., Brundage et al., 2000; Brundage et al., 2000; Fiset et al., 2000; Whelan 
et al., 2004). 
3. Total scores on the knowledge scale would increase following use of the guided 
decision aid more than the comparison group scores would increase following use of 
the pamphlet. This was hypothesized because several studies have demonstrated that 
use of decision aids increased scores on measures of knowledge (e.g., Brundage et al., 
2000; Brundage et al., 2000; Schapira et al., 1997; Whelan et al., 2003; Whelan et al., 
2004). Additionally, it was thought that since the guided decision aid group would also 
be completing written exercises to help make a decision, they would be spending more 
time reading and thinking about the materials, and would therefore likely retain more 
information. 
Exploratory Questions of Changes in Treatment Preference. 
1. Will there be an interaction between treatment options, time, and groups for ratings of 
preference? In other words, will ratings of preference for treatment options change 
across time for the guided decision aid group and/or the comparison group? It was 
expected that a significant interaction would indicate that preference for the treatment 
options changed more over time for the guided decision aid group than the comparison 
group. The direction of change in preference for each treatment could not be predicted 
because no other study has examined the effect of an aid on treatment preference in 
NHL. However, it was possible that initially patients would show higher preference for 
common cancer treatments such as chemotherapy and radiation, simply because these 
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treatments are more familiar. Then, after use of the decision aid, we expected that 
preference for familiar treatments would decrease, while preference for less familiar 
treatments such as biologic therapy would increase. We expected that the decision aid 
group would show a greater change in treatment preference than the comparison group 
because other studies have found significant changes in treatment preferences 
following the use of an aid (e.g., Feldman-Stewart et al., 2001; Sebban et al., 1995). 
2. In addition to examining ratings of treatment preference, participants were also asked 
to rank the treatment options in order of preference. Ratings of treatment preference 
would show how strongly participants preferred each option, while rankings of 
treatment preference would reveal which treatments the participants would choose 
when selecting between the treatment options. The second exploratory question was as 
follows: Will there be an interaction between treatment options, time, and groups for 
rankings of preference? In other words, will rankings of preference for treatment 
options change across time for the guided decision aid group and/or the comparison 
group? It was expected that a significant interaction would indicate that preference for 
the treatment options changed over time for the guided decision aid group more than 
the comparison group. The direction of change in ranking for each treatment could not 
be predicted because no other study has examined the effect of an aid on treatment 
preference in NHL. However, as discussed above, it is possible that initially patients 
would rank common cancer treatments higher. Then, after use of the decision aid, we 
would see rankings for familiar treatments decrease, while preference for less familiar 
treatments such as biologic therapy increase. We expect that the guided decision aid 
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group would show a greater change in rankings than the comparison group because 
other studies have found significant changes in ranking of treatment following the use 
of an aid (e.g., Feldman-Stewart, 2001). 
Exploratory Predictor Analyses. To extend knowledge of participant characteristics that 
may predict changes in decision satisfaction and decisional conflict scores following use of 
decision aids, an exploratory analysis was conducted. Participant characteristics that could 
account for some of the variability in change in total scores following use of the guided decision 
aid were examined as predictor variables including age, gender, education, anxiety, depression, 
need for cognition, and monitoring/blunting. We were also interested in exploring how much 
variability in knowledge gained from the guided decision aid that was accounted for by the time 
spent reading the decision aid and time spent making the decision. The following exploratory 
questions were examined in the guided decision aid group. 
1. How much of the variance for change in satisfaction with decision was accounted 
for by each of the following: age, gender, education, anxiety, depression, need for 
cognition, and monitoring? 
2. How much of the variance for change in decisional conflict was accounted for by 
each of the following: age, gender, education, anxiety, depression, need for 
cognition, and monitoring? 
3. How much of the variance for change in knowledge was accounted for by each of 
the following: reading time and time spent making decision? 
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Method 
The study was conducted in two phases. The first phase included the development of the 
guided decision aid and the second phase included the evaluation of the decision aid. 
Phase I: Development 
Participants 
 Fifty-one patients (26 males and 25 females) aged 18 and older who had experienced 
treatment for follicular NHL were asked to participate in the study. Twenty participants (10 
males and 10 females) agreed to participate. These participants were recruited from a list of 
patients from the Hemotology/Oncology program at the Mary Babb Randolph Cancer Center in 
Morgantown, WV. Participants were randomly assigned to one of three groups: a decision aid 
input group, decision aid evaluation, and a scenario evaluation group. See Table 1 for a list of 
participants in each group. All participants were able to read. 
Table 1 
Number of Patient Participants per Groups 
______________________________________________________________________________ 
Group    Number of Participants  Males  Females                        
______________________________________________________________________________ 
 
Decision aid input   9        4      5 
 
Decision aid evaluation  6        3      3 
 
Scenario evaluation   5        3      2 
 
______________________________________________________________________________ 
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Measures 
Guided Decision Aid. The decision aid was developed for patients with indolent follicular 
lymphoma who have experienced a recurrence of their disease and are now attempting to 
determine which treatment to use to bring the disease into remission and/or to prolong life (See 
Appendix A for a copy of the Guided Decision Aid). The decision aid was created based on the 
previously described Ottawa Decision Framework (OConnor et al., 1998). First, the decision aid 
described the purpose of the aid. Then, information was included about the lymphatic system, 
Lymphomas, and follicular Lymphoma. Next, information about the treatment options for 
follicular NHL was described along with lists of the risks and benefits of the treatment options. 
The next section included questions to ask a physician about which treatments were available to 
the patient. An example of a patient making a decision about treatment was then described. 
Sources for additional information were then listed. The final section of the aid included value 
clarification exercises based on worksheets created by OConnor and Jacobsen (2004). The 
exercises contained questions that helped patients explore values that were important to them in 
treatment selection and exercises to help patients weigh the pros and cons of each option. The 
format of the aid was a booklet. 
Semi-Structured Interview. This was a five-item measure that was administered over the 
telephone. It included open-ended questions that assessed what information content was 
important to include in the content of each section of the decision aid and the content that was 
important to include in a scenario of a patient with follicular lymphoma (See Appendix B for 
questions included in this interview). This interview took about 15 minutes to administer. 
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Decision Aid Evaluation Questionnaire. This measure included Likert-type ratings and open-
ended questions for each section of the decision aid that participants used to evaluate the content 
of the decision aid for the utility of each section of the decision aid (See Appendix C for this 
questionnaire). Utility was defined as the extent to which the patient believed that the 
informational content offered would be helpful in making a treatment decision. Sections of the 
decision aid that were created included the lymphatic system, lymphomas and follicular 
lymphoma, chemotherapy, radiation, biologic therapy, stem cell transplantation, watch and wait, 
and clinical trials. Likert-type questions were listed for each section related to usefulness, 
relevance, clarity, understandability, and applicability. Each item was rated from 1 (disagree) to 
4 (agree). The scale also included open-ended questions for each section of the decision aid 
regarding items participants thought should be added, deleted, or modified. 
Patient Demographic Questionnaire. This questionnaire was a measure created by the 
investigator to gather information on sociodemographic characteristics including age, gender, 
race, and education (See Appendix D for a copy of this scale).  
Patient Scenario. This was a description of a patient with recurrent follicular lymphoma who 
needed to make a decision about treatment (See Appendix E for a copy of this scenario). The 
scenario described the patients age, gender, type of lymphoma, length of time in remission, 
marital status, children, and the current treatment options that the patient was considering. 
Patient Scenario Evaluation Questionnaire. This questionnaire was designed by the investigator 
to request patient input about the previously described patient scenario (See Appendix F for a 
copy of this questionnaire). Patients were asked to rate the believability of the patient scenario on 
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a scale of 1 (not very believable) to 4 (very believable). Patients were also asked open-ended 
questions about what aspects of the scenario they felt should be added, deleted, or modified. 
Procedures 
The development of the guided decision aid involved several steps. First, thirteen patients 
(7 males and 6 females) were mailed a consent form, the patient demographic questionnaire, a 
form for the patient to fill in his or her name and convenient times to be telephoned, and a 
stamped envelope with the researchers address. Patients were requested to complete and mail all 
materials to the researcher if interested in participating the study. If the researcher did not receive 
materials within one week, patients were telephoned by the researcher to ask if they had 
questions about the study.  Nine patients (4 males and 5 females) agreed to participate and were 
administered the semi-structured interview by the investigator over the telephone. Once 
important information to include in the aid was determined through these interviews, literature 
on available treatments for the recurrence of NHL was reviewed. Then, the decision aid was 
created using the information from the interviews and the literature review according to the 
format described above. 
After the guided decision aid was created, it was evaluated for face validity and content 
validity by two oncologists and one pharmacist who specialized in hematological malignancy. 
The content of the decision aid was then altered according to their recommendations. 
 Next, the decision aid, patient demographic questionnaire, and the decision aid evaluation 
questionnaire were mailed to 28 patients (15 males and 13 females) who had not yet participated 
in the study. These participants were asked to evaluate the utility of the decision aid based on the 
questions on the decision aid evaluation questionnaire. Participants were asked to return the 
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patient demographic questionnaire and the decision aid evaluation questionnaire to the 
investigator in a self-addressed stamped envelope. If materials were not received from the 
participants within one week after mailing, the investigator telephoned the patients to determine 
if they had questions about the materials. Six participants (3 males and 3 females) returned the 
questionnaires. Comments from the patients on the decision aid evaluation questionnaire were 
used to modify the decision aid accordingly. 
 Finally, a scenario of a patient who was attempting to make a decision about treatment 
for recurrent follicular lymphoma was created based upon information obtained in a literature 
review, input from an oncologist specializing in the study of hematological malignancies, and 
input from patients in the semi-structured interview. This scenario was used in the second phase 
of the study as a basis for treatment decisions. The scenario described the patients age, gender, 
type of lymphoma, length of time in remission, marital status, children, socioeconomic status, 
and the current treatment options that the patients was considering. This scenario was mailed to 
10 patients (4 males and 6 females) who had not yet participated in the study along with the 
patient demographic questionnaire and patient scenario evaluation questionnaire. Participants 
were asked to complete and return the patient demographic questionnaire and the patient 
scenario evaluation questionnaire to the investigator in a self-addressed stamped envelope. If 
materials were not received from the participants within one week after mailing, the investigator 
telephoned the patients to determine if they had questions about the materials. Five participants 
(3 males and 2 females) returned the questionnaires. Comments from the patients on the patient 
scenario evaluation questionnaire were used to modify the patient scenario accordingly. 
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Phase II: Non-patient Evaluation 
Participants 
 
Seventy-two community-dwelling adults (38 males and 34 females) aged 40 to 80 years 
who had never been diagnosed with cancer were asked to participate in this study. This age 
group was chosen because the incidence for NHL is highest during this age period (National 
Cancer Institute, 2002). Sixty participants (30 males and 30 females) ages forty to seventy-nine 
agreed to participate in the study. As discussed previously, the reason that participants were 
chosen who had never been diagnosed with cancer was that this allowed for some control over 
variability contributed by participant knowledge of NHL and emotional responses to the cancer 
diagnosis. All participants were able to read and write. Participants were assigned randomly to 
either an experimental group that received the guided decision aid created in Phase I, or a 
comparison group that received the comparison decision aid. 
Measures 
Comparison Decision Aid. The comparison decision aid was designed to be similar to the 
standard of care brochure that patients might receive in a hospital. No brochures were 
available specifically for follicular lymphoma; thus, the guided decision aid was pared down to 
include information that one might find in such a brochure (See Appendix G for a copy of the 
Comparison Decision Aid). The comparison decision aid has the same structure as the decision 
aid with several sections removed. The comparison decision aid does not include the purpose of 
the aid, lists of the risks and benefits of the treatment options, questions to ask a physician, an 
example of a patient making a decision about treatment, or value clarification exercises. 
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Decisional Conflict Scale. The Decision Conflict Scale is a nine item rating scale of decision 
uncertainty (OConnor, 1995). According to the creators of this scale, decisional conflict is a 
state of uncertainty about the course of action to take (OConnor, 1995, p. 25). The rating scale 
consists of three sections: decision uncertainty, factors contributing to uncertainty, and perceived 
effective decision making. Each item is rated on a scale from 1 (strongly agree) to 5 (strongly 
disagree) and negative items are reverse scored. Higher scores indicate greater decisional 
conflict. When completing the scale, participants were asked to reflect on the decision they just 
made. This scale has been psychometrically evaluated in patients making decisions about breast 
cancer screening and influenza immunization (OConnor, 1995). In this evaluation, the decision 
conflict scale was shown to have adequate test-retest reliability (r = 0.81), internal consistency 
for the total scale (alpha ranged from 0.78 to 0.92), and internal consistency for the subscales 
(alpha ranged from 0.58 to 0.92). The authors also reported that the scale had high discriminant 
validity in that scores were significantly higher on most subscales for individuals who were 
unsure of their decision than individuals who had accepted or rejected the influenza 
immunization or cancer screening. This instrument was chosen because it has been frequently 
used within the cancer decision aid literature to measure for treatment decision uncertainty and 
because it has been shown to have psychometrically sound properties (OConnor, 1995). 
The Satisfaction with Decision Scale. This scale was designed as a global measure of satisfaction 
with a decision (Holmes-Rovner et al., 1996). The Satisfaction with Decision Scale is a 6 item 
measure that asks participants to rate each item on a 5-point Likert scale from 1 (strongly 
disagree) to 5 (strongly agree). Higher scores indicate higher satisfaction with the decision. This 
scale was evaluated for discriminant validity in women considering hormone replacement 
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therapy (Holmes-Rovner et al., 1996). The authors examined the relation between the scale and 
seven measures of decision uncertainty, provider satisfaction, decision confidence, and 
knowledge. The authors found that the scale scores correlated poorly with scores of scales 
measuring knowledge (r = 0.22) and provider satisfaction (r = 0.2). The scale was moderately 
inversely related to the decisional conflict scale scores (r = -0.54) and was moderately related to 
decision confidence (r = 0.64). The authors determined that the Satisfaction with Decision Scale 
measured a unique construct in decision making because the scale items showed much higher 
correlations among themselves as compared to items from other measures of decision making. 
This scale was chosen to measure how satisfied participants were with their treatment selection 
and because there is evidence to support its validity (Holmes-Rovner et al., 1996). 
Ratings and Rankings of Treatment Preference. This scale was created by the investigator (See 
Appendix H for a copy of this scale). This scale listed each of the treatment options mentioned in 
the decision aid and asked the participants to rate each treatment on a 4-point Likert-type scale. 
The ratings were anchored thusly: 1 = would not prefer, to 4 = would definitely prefer. This scale 
was used as a measure of the strength of preference for each treatment option. The scale then 
asks participants to rank the treatment options in order from 1 = best to 6 = worst. 
Knowledge Test. This test was created by the investigator to evaluate knowledge of the content 
of the guided decision aid and comparison decision aid (See Appendix I for a copy of this 
questionnaire). The test consisted of twenty multiple choice questions based on each 
informational content area of the guided decision aid and comparison decision aid. This measure 
did not include questions related to lists of risks and benefits, questions to ask the doctor, 
resources, or the patient example. The test was evaluated by two oncologists and one pharmacist 
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to determine whether the information in the questionnaire was representative of the information 
presented in the guided decision aid and comparison decision aid. Before administration to 
participants, this test was evaluated with ten psychology graduate students. The graduate students 
scored an average of 10.2 (SD = 3.55) before reading the decision aid and an average of 15.8 
(SD = 2.44) after reading the decision aid. There was a significant increase in scores (t = -4.36, p 
< .05), which indicated that the knowledge test was an adequate measure of knowledge gained 
following reading of the decision aid. 
Sociodemographic Questionnaire. This questionnaire was a measure created by the investigator 
to gather information on sociodemographic characteristics including age, gender, race, and 
education (See Appendix J for a copy of this scale). The questionnaire also asked participants 
whether they know someone with cancer, know someone with lymphoma, or have helped 
someone make a decision about treatment for cancer. 
Spielberger Trait Anxiety Inventory (STAI-Trait). This inventory is a measure of trait anxiety, 
which is the individuals general level of anxiety in response to stressful situations (Spielberger, 
1983). The scale includes 20 items on which patients are asked to rate their general feeling on 
a 4 point Likert-type scale from 1 (almost never) to 4 (almost always). Higher scores indicate 
greater trait anxiety. This scale was evaluated for internal consistency in 391 college students 
(Tanaka-Matsumi & Kameoka, 1986). The scale showed adequate internal consistency with a 
Cronbachs alpha value of .90. The authors also found that total scores on this scale correlated 
with total scores on other measures of anxiety (r = .38 to .72). The total scale score was also 
shown to correlate with total scores on other measures of anxiety in a sample of older adults (r = 
.43 to .57; Stanley et al., 1996). This scale also showed high test-retest reliability in this sample 
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(r = .84). This scale was chosen because it is a widely used measure of trait anxiety and because 
it has been shown to have psychometrically sound properties. 
Center for Epidemiologic Studies Depression Scale (CES-D). This scale is a measure of general 
depression (Radloff, 1977). The CES-D is a 20-item measure in which participants indicated on a 
Likert-type scale how often they experienced symptoms within the last week from 0 ("rarely or 
none of the time") to 3 ("most or all of the time"). Four of the items are reversed scored. Higher 
scores indicate more depressive symptoms. This scale was evaluated for internal consistency in 
117 cancer patients and 62 healthy adults (Hann et al., 1999). The scale showed internal 
consistency with a Cronbach's alpha of 0.89 in patients and 0.87 in healthy adults. Test-retest 
reliability over 2.5 weeks was also adequate (r = 0.57 in patients and r = 0.51 in healthy adults). 
The authors also found that the CES-D correlated negatively with a measure of mental health 
functioning (r = -.065 for patients and r = -.67 for healthy adults). This measure was chosen 
because it is a widely used measure of depression and because of its sound psychometric 
properties. 
Need for Cognition (short form). This scale was designed to measure an individuals desire to 
engage in effortful cognitive activity (Cacioppo et al., 1996). The scale is an 18-item measure on 
which participants are asked to rate statements of desire for cognitive activities on a 5-point 
Likert-type scale from 1 (extremely uncharacteristic) to 5 (extremely characteristic). Nine of the 
items are reversed scored. Higher scores indicate greater need for cognition. Internal consistency 
values for this scale range from a Cronbachs alpha of .65 to .97 (Cacioppo et al., 1996). The 
scale has also been examined for discriminant validity and has been shown to correlate poorly 
with measures of other constructs (values of r ranging from -.45 to -.08). Also, this scale has 
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been shown to correlate with other measures of cognitive motivation (r = .20 to .51). This scale 
was chosen because it is a widely used measure of desire for cognitive activity and because there 
is some evidence of its psychometric properties. 
Miller Behavioral Style Scale (MBSS). This scale was designed to measure two styles of coping 
with stressful information including blunting (preference for distraction from stressful 
information) and monitoring (preference for attending to stressful information) (Miller, 1987). 
Participants were asked to imagine four stressful scenes. Following each scene, participants were 
asked (yes/no) whether they would respond in the manner indicated in each of eight statements 
(4 monitoring statements and 4 blunting statements). The scale results in two subscale scores, 
one of monitoring and one of blunting. Higher scores on each subscale indicate higher levels of 
each coping style. A total score can then be calculated by subtracting the blunting subscale score 
from the monitoring subscale score. Higher total scores indicate more monitoring behavior. This 
scale showed adequate test-retest reliability over a 4 month time period (r = .72 for the 
monitoring subscale and r = .75 for the blunting subscale; Miller, 1987). This scale has also been 
shown to correlate moderately with a measure of a similar construct (r = .32; Ludwick-Rosenthal 
et al., 1993). This scale has also been shown to correlate poorly to moderately with measures of 
other constructs (r = -.28 to .2). The authors suggest using the monitoring subscale in research 
involved with this questionnaire, as this has shown the best predictive ability; thus, the 
monitoring subscale was used in analyses in the current study. This scale was chosen because it 
is a widely used measure of stressful information coping style and because there is some 
evidence of its psychometric properties. 
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Opinion of the Decision Aid. This questionnaire was designed by the investigator to determine 
what aspects of the decision aid were most and least helpful to the decision-making process. See 
Appendix K for a copy of this questionnaire. This questionnaire included two open-ended 
questions that asked participants to report the aspects they felt were most and least helpful. 
Procedure 
 Participants were recruited from churches, clubs, and by word of mouth in Winona, MN. 
Data collection took place at churches or homes, depending upon what was convenient for each 
participant. Directly before data collection, the study protocol was described to the participants 
by the investigator and written informed consent was gathered at that time. Participants were 
asked to fill out the study materials described below after the protocol had been described to 
them by the investigator. The investigator was nearby to answer any questions. 
 First, the participants were instructed to complete the sociodemographic questionnaire, 
State Trait Anxiety Inventory, Need for Cognition Scale, Center for Epidemiologic Studies 
Depression Scale, and Miller Behavioral Style Scale. Then, the participants were instructed to 
read the patient scenario (as described in Phase I). They were asked to make a treatment 
selection as though they were the person described in the scenario. Participants completed the 
first set of questionnaires, which included the knowledge test, ratings and rankings of treatment 
preference, satisfaction with decision scale, and the decisional conflict scale. Once these 
materials were completed, they were collected from each participant. Then, the participants were 
given and instructed to either read and complete the guided decision aid or the comparison 
decision aid depending upon group. Participants were asked to record the time they began to read 
the materials and the time they stopped reading the materials. Those in the guided decision aid 
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group were also instructed to complete the value clarification exercises at the end of the aid. 
Once the participants had finished with the guided decision aid or the comparison decision aid, 
these items were collected from them. Finally, the participants were given and asked to complete 
the second set of questionnaires, which included the ratings and rankings of treatment 
preference, knowledge test, satisfaction with decision scale, and the decisional conflict scale. 
Participants were asked to record the time that they finished the ratings and rankings of treatment 
preference. For the pre and post decision aid questionnaires, the order of the satisfaction with 
decision scale and the decisional conflict scale were randomized to preclude order effects. 
Participants in the decision aid group were also asked to complete the opinion of the decision aid 
questionnaire. 
 Participants were offered the opportunity to fill out a raffle ticket for a drawing that took 
place once all data were collected. The participants had the opportunity to win either a one-
hundred dollar check or a twenty-five dollar gift certificate to Culver's restaurant. Once data 
collection was completed, winning raffle tickets were drawn randomly and winners were notified 
via telephone. Each participant was offered a wristband from the Leukemia and Lymphoma 
Society. 
Design, Analysis, and Data Management 
 A pre/post design was used to detect change in scores on measures of decisional conflict, 
decision satisfaction, and knowledge. Total scores on the first three measures before and after 
using the guided decision aid or comparison decision aid were compared. A mixed 2 (group) X 2 
(time) ANOVA was used to detect these changes. For each ANOVA, time was the within subject 
variable (pre-post), while group was the between group variables (decision aid and pamphlet).   
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Additionally, the treatment preference ratings for each of the six treatment options before 
and after using the decision aid or pamphlet were compared. Treatment preference rankings for 
each of the six treatment options before and after using the decision aid or pamphlet were also 
compared. A mixed 2 (group/between) X 2 (time/within) X 6 (treatment options/within) 
ANOVA was used to detect these changes.  
 To determine the sample size for these analyses, a power analysis was performed for 
repeated-measures ANOVA. This analysis revealed that the current sample size was sufficient 
for a power of 80% (p = .05) and an effect size of f = .40 (as used by Goel et al., 2001). 
To extend knowledge of participant characteristics that may predict changes in scores 
following use of decision aids, exploratory analyses were conducted. Participant characteristics 
that could account for some of the variability in change in total scores following use of the 
guided decision aid were examined as predictor variables in a stepwise multiple regression 
analysis. Age, gender, and total scores on the STAI-Trait, CES-D, Need for Cognition Scale, and 
monitoring subscale of the MBSS were used as predictors. Scores on the decisional conflict scale 
and the satisfaction with decision scale served as criterion variables in two multiple regression 
analyses. Time spent reading the guided decision aid and time spend making the decision were 
also examined as potential predictors in a third stepwise multiple regression analysis. Total 
scores on the knowledge questionnaire served as the criterion variable in this analysis. Raw 
change scores as well as residualized change scores served as criterion variables in the multiple 
regression analyses. 
Out of 60 participants in Phase II, only two participants had missing data. Both 
participants were from the guided decision aid group. One participant did not answer one 
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question on the CES-D; while the other did not answer one question on the CES-D and one 
question on the STAI-Trait. It appeared that these items were accidentally missed. For these 
participants, missing scores were replaced with the mean score for the items on the respective 
measure. 
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Results 
 The results of this study are divided into two phases. Phase I includes information related 
to the patient participation in the development of the guided decision aid. Phase II includes 
results of the evaluation of the guided decision aid in a non-patient sample. 
Phase I 
 Phase I is divided into four sections. First, demographic information of the participating 
patients is described. Then, results of interviews with participants regarding material to include 
in the decision aid is then presented. Next, participants evaluations of the patient vignette are 
described. Finally, participants evaluations of the guided decision aid are presented.  
Demographic Information for Patient Participants  
Participants included 20 adults, 10 males and 10 females, who had been diagnosed with 
follicular lymphoma (M age = 61.85, SD = 8.399; please see Table 2 for participant demographic 
information). All participants were Caucasian. Most participants were moderately educated with 
either a high school degree (30%) or some college education (30%). Many participants had not 
graduated high school (25%). Several participants were highly educated and either graduated 
college (5%) or attended graduate school (10%). 
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Table 2 
Demographic characteristic of Patient Participants 
______________________________________________________________________________ 
Variable                         
______________________________________________________________________________ 
 
Number of                                                          20                                               
patients    
         
Age [Mean (SD)]                                          61.85 (8.39)                             
Gender 
      Male                                                             10                                            
      Female                                                         10                                           
 
Ethnicity 
     Caucasian                                                    100%                                      
 
Education 
     Some high school                                         25%                                             
     High school grad                                          30%                                       
     Some college                                                30%                                    
     College grad                                                  5%                                    
     Graduate school                                            10%                                        
______________________________________________________________________________ 
 
Interviews with Participants Regarding Content of Decision Aid 
 Before the decision aid was written, participants were telephoned and interviewed to 
discuss content they felt was important to include in the decision aid. Nine participants (4 males 
and 5 females) participated in telephone interviews. Participant responses to the interview 
questions are listed in Appendix L. Generally, participants offered a variety of opinions related to 
their individual situations. Regarding information participants believed was important to include 
about the disease, common responses included information about symptoms of the disease and 
how quickly the disease spreads. Several common responses regarding information about 
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treatment options included information about side effects, lengths of procedures, and both risks 
and benefits of treatments. Participants offered a variety of questions that one might consider 
asking a physician. Several common themes for questions included side effects of treatments, 
procedure of treatments, and effects of the treatments on the body. Regarding format of the 
decision aid, most participants felt that pictures and patient examples would be helpful. Most felt 
that there should be a combination of listed and paragraph information. There was a range of 
preferred lengths of the decision aid, which ranged from four pages to twenty pages. Common 
participant suggestions were considered in development of the decision aid. 
 Participants were also interviewed regarding information they thought would be helpful 
to include in a patient vignette. Again, a variety of information was suggested. Common themes 
suggested by participants included describing family information, extent of patient disease, and 
treatments available. These suggestions were incorporated into the creation of the patient 
vignette.  
Evaluation of Patient Vignette 
 Five patient participants (3 males and 2 females) responded to a questionnaire requesting 
feedback on the accuracy and believability of the patient vignette. Patients were asked to report 
how believable they found the patient vignette, using a 4-point rating scale, where 1= not very 
believable and 4= very believable. The mean rating of believability was 3.8 (SD = .45), which 
indicates that most participants felt the patient vignette was very believable. Participants were 
also asked to provide feedback regarding changes that should be made to the vignette to make it 
more believable. Participant feedback is found in Appendix M. The most common suggestion 
given by participants was to include more information about treatment options; however, this 
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information was purposefully excluded from the patient vignette because this information was 
presented in the decision aid and comparison group pamphlet. Other information suggested was 
incorporated in the patient vignette such as whether insurance would cover options. 
Evaluation of Decision Aid 
 Six patient participants (3 males and 3 females) responded to a questionnaire evaluating 
the accuracy and utility of the decision aid. Participants rated how much they agreed with 
statements about the sections of the decision aid on a 4-point scale, where 1= disagree and 4= 
agree. The sections were the lymphatic system, lymphoma and follicular lymphoma, 
chemotherapy, radiation, biologic therapy, stem cell transplant, watch and wait, and clinical trial. 
Each section had a highest possible score of twenty. Overall, participants gave high ratings for 
all sections of the decision aid, indicating that patients felt the sections were useful and accurate 
(see Table 3). Suggestions made by participants regarding the content of the decision aid are 
listed in Appendix N. Several participants did not make suggestions for changes to the decision 
aid. A common suggestion was to make the lymphatic system diagram larger, and thus a larger 
diagram was incorporated in the decision aid. Other responses were quite varied and appeared to 
represent specific preferences of each rater. All responses were considered in the final Decision 
Aid product.  
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Table 3 
Mean Ratings of Accuracy and Utility of Decision Aid Organized by Section of the Decision Aid 
______________________________________________________________________________ 
Section                                                                         Mean Rating (SD) 
______________________________________________________________________________ 
 
Lymphatic System      19.17 (.98) 
 
Lymphoma and Follicular Lymphoma   19.50 (.84) 
 
Chemotherapy       19.60 (.89) 
 
Radiation       19.40 (1.34) 
 
Biologic Therapy      19.33 (1.03) 
 
Stem Cell Transplant      19.80 (.45) 
 
Watch and Wait      18.33 (4.08) 
 
Clinical Trial       18.00 (2.00) 
______________________________________________________________________________ 
 48
Phase II 
 Phase II addresses results related to the evaluation of the guided decision aid and is 
divided into several sections. The first section addresses demographic information related to the 
non-patient sample. Next, results related to three hypotheses evaluating change in Satisfaction 
with Decision, Decisional Conflict, and Knowledge of Follicular Lymphoma are described. 
Results related to exploratory analyses are then described that evaluate change in Ratings of 
Preference for Treatment Options and Ranking of Preference for Treatment Options across time 
and between the decision aid and comparison groups. Results related to exploratory analyses of 
predictors of changes in Satisfaction with Decision scores and Decisional Conflict scores are 
then presented. Finally, results of exploratory analyses of reading time and decision time as 
potential predictors of change in knowledge scores are then described. Alpha was set at the .05 
level for all analyses. 
Demographics 
 Participants included 60 adults (30 males and 30 females) aged 40 to 79 years (M = 
55.35, SD = 9.19; see Table 4 for participant demographic information). All participants were 
Caucasian. The participants were highly educated, and all participants received at least a high 
school diploma. Most of the participants had obtained at least some college education (23.3% 
had attended some college and 26.7% were college graduates). The largest percentage of 
participants had attended graduate school (38.3%). A small percentage had received only a high 
school diploma (11.7%). All participants had some prior experience with cancer in that all 
participants knew someone with cancer. Forty percent of participants knew someone with 
lymphoma, and 30% had helped someone make a decision about treatment for cancer.  
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Table 4 
Demographic characteristics, Participant experience with cancer 
______________________________________________________________________________ 
Variable                    Decision Aid Group             Comparison Group                          All 
______________________________________________________________________________ 
 
N                                         30                                            30                                          60      
         
Age [M (SD)] a             59.03 (9.14)                            55.67 (9.09)                           57.35 (9.19) 
Male                                    15                                           15                                             30 
Female                                15                                           15                                             30 
 
Ethnicity 
     Caucasian                  100%                                      100%                                       100% 
 
Educationb 
     Some high school         0                                            0                                                0 
     High school grad          10%                                      13.3%                                        11.7% 
     Some college                23.3%                                   23.3%                                       23.3% 
     College grad                 26.7%                                   26.7%                                       26.7% 
     Graduate school           40%                                       36.7%                                      38.3% 
 
Knew someone with  
cancer 
    Yes                               100%                                     100%                                        100% 
    No                                 0%                                         0%                                            0% 
 
Helped make cancerb 
treatment decision 
    Yes                                23.3%                                   36.7%                                        30% 
     No                                76.7%                                   63.3%                                        70% 
 
Knew someoneb  
with lymphoma 
     Yes                              33.3%                                   46.7%                                         40% 
     No                               66.7%                                   53.3%                                         60% 
______________________________________________________________________________
a A two-tailed t-test revealed no significant age differences between groups (t = 1.43, p = .158). bA chi-square test 
revealed no significant differences between groups regarding education [χ2(3) = .186, p = .98], number who helped 
make a cancer decision [χ2(1) = .1.27, p = .26] , and number who knew someone with lymphoma [χ2(1) = 1.11, p = 
.29]. 
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Hypothesis 1: There will be a significant interaction between groups and time for satisfaction 
with decision. The guided decision aid group was hypothesized to have a greater increase in 
satisfaction with decision than the comparison group. 
 The results of a Mixed 2 (groups) x 2 (time) ANOVA revealed increases in satisfaction 
with decisions for both the guided decision aid and comparison groups [F (1, 58) = 51.2, p < 
.001; see Table 5 for results]. However, hypothesis 1 failed to be supported. No interaction was 
found. Thus, increase in satisfaction with decision for the guided decision aid group was no 
greater than that of the comparison group [F (1, 58) = 1.78, p = 0.187]. Means for Satisfaction 
with Decision are displayed in Figure 1. There was a significant main effect for group [F (1, 58) 
= 5.71, p < .05]. 
Table 5 
Mixed ANOVA, Satisfaction with decision difference between decision aid and comparison 
groups across time 
______________________________________________________________________________ 
Source                                    df                         F                             η2                      p 
______________________________________________________________________________ 
 
Within Subjects 
 
Time                                       1                        51.2                         0.47                  <.001 
 
Time*Group                           1                        1.78                         0.03                   0.187 
 
Within Error                          58               MS = 9.06 
 
______________________________________________________________________________ 
 
Between Subjects 
 
Group                                   1                         5.71                          0.09                  0.02 
 
Between Error                      58               MS = 32.8 
______________________________________________________________________________ 
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Figure 1. Satisfaction with Decision for Decision Aid and Control Groups across Time 
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Hypothesis 2: There will be a significant interaction between groups and time for decisional 
conflict. The guided decision aid group was hypothesized to have a greater decrease in decisional 
conflict than the comparison group. 
 The results of a Mixed 2 (groups) x 2 (time) ANOVA revealed a main effect for time [F 
(1, 58) = 96.9, p < .001; see Table 6 for results]. Decisional conflict decreased significantly for 
both groups. However, hypothesis 2 was not supported. No interaction was found between the 
groups and time. Thus, decisional conflict did not decrease significantly more for the guided 
decision aid group than the comparison group [F (1, 58) = 1.84, p = 0.18]. Means for decisional 
conflict across time for both groups are presented in Figure 2. There was a significant main 
effect for group [F (1, 58) = 5.05, p < .05]. 
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Table 6 
 
Mixed ANOVA, Decisional Conflict difference between guided decision aid and comparison 
groups across time 
______________________________________________________________________________ 
Source                                    df                         F                             η2                      p 
______________________________________________________________________________ 
 
Within Subjects 
 
Time                                       1                        96.9                         0.63                  <.001 
 
Time*Group                           1                        1.84                         0.03                   0.18 
 
Within Error                          58               MS = 22.82 
 
______________________________________________________________________________ 
 
Between Subjects 
 
Group                                   1                         5.05                          0.08                  0.028 
 
Between Error                      58               MS = 65.39 
 
______________________________________________________________________________ 
 
Figure 2. Decisional Conflict for Decision Aid and Control Groups across Time 
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Hypothesis 3: There will be an interaction between groups and time for knowledge. The guided 
decision aid group would have a greater increase in knowledge than the comparison group. 
 A Mixed 2 (groups) x 2 (time) ANOVA yielded a main effect for time [F (1, 58) = 
143.46, p < .001; see Table 7 for results]. Thus, knowledge increased significantly after reading 
the guided decision aid or comparison group pamphlet. However, hypothesis 3 was not 
supported. No interaction was found between time and groups, suggesting that knowledge did 
not increase more for the guided decision aid than the comparison group [F (1, 58) = 0.03, p = 
0.87]. Means for knowledge across time for both groups are presented in Figure 3. 
 
Table 7 
 
Mixed ANOVA, Knowledge difference between guided decision aid and comparison groups 
across time 
______________________________________________________________________________ 
Source                                    df                         F                             η2                      p 
______________________________________________________________________________ 
 
Within Subjects 
 
Time                                       1                        143.46                     0.71                  <.001 
 
Time*Group                           1                        0.03                         0.00                   0.87 
 
Within Error                          58               MS = 9.06 
 
______________________________________________________________________________ 
 
Between Subjects 
 
Group                                    1                         0.34                          0.006                 0.56 
 
Between Error                      58               MS = 14.2 
 
______________________________________________________________________________ 
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Figure 3. Knowledge for Decision Aid and Control Groups across Time 
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Exploratory Treatment Preference Analysis 1: Will there be an interaction between treatment 
options, time, and groups for ratings of treatment preference? In other words, will ratings of 
preference for treatment options change across time for the guided decision aid group and/or the 
comparison group? 
 Participants were asked to rate their preference for each of the six treatment options on a 
4-point scale (1 = would not prefer and 4 = would definitely prefer). Participants were asked to 
rate the treatments before and after reading either the guided decision aid or comparison decision 
aid. Analyses examined whether the guided decision aid group would have more changes in 
ratings of preference across time for the treatment options than the comparison group. This 
question was examined using a Mixed 2 (group) X 2 (time) X 6 (treatment options) ANOVA. 
Mauchlys test of sphericity revealed that the assumption of sphericity was violated for the main 
effects of Treatment Options [χ2(14) = 58.3, p < .001] and Treatment Options x Time [χ2 (14) = 
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67.9, p < .001].  Degrees of freedom were corrected using the Greenhouse-Geisser correction (ε 
= 3.55 for Treatment Options and 3.37 for Treatment Options x Time). Mean ratings for each 
treatment option for each group are presented in Figures 4 and 5.  
 There was a significant main effect for treatment options [F(3.55, 205.6) = 4.75, p < .01]; 
full results are presented in Table 8]. That is, ratings of preference for treatment options differed. 
However, there was not a significant interaction between treatment options and groups [F(3.55, 
205.6) = .16, p = .948]. Thus, the guided decision aid group did not rate the treatment options 
significantly different from the comparison group. 
Additionally, there was a significant main effect for time [F(1, 58) = 5.8, p < .05]. 
Ratings of treatment options were significantly higher during the second rating than the first 
rating. However, there was not a significant interaction effect for time and groups [F(1, 58) = 
3.22, p = .078]. That is, the guided decision aid group did not rate the treatment as significantly 
different from the comparison group across time. A significant interaction was found between 
treatments options and time [F(3.37, 195.2) = 3.01, p < .05].  Thus, ratings of treatment options 
changed across time. 
There was not a significant three-way interaction between treatment options, time, and 
groups [F(3.37, 195.2) = 1.94, p = .12]. That is, there was not a significant difference between 
groups in ratings of treatment options across time. Since there was not a significant three-way-
interaction as suggested in the exploratory question, follow-up analyses of the simple effects of 
the highest order interaction, treatment options and time, were conducted. Analyses of simple 
simple effects were conducted to follow this significant interaction using Least Significant 
Difference test with a Bonferroni adjustment for alpha. For the groups combined, ratings of 
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biologic therapy increased following use of the guided decision aid or comparison decision aid (p 
< .01). See Table 9 for estimated marginal means for the groups combined. Ratings of watch and 
wait also increased ( p < .05). Thus, it appears that although we did not see a difference between 
groups, both groups rated biologic therapy, and watch and wait, as more preferable following use 
of the reading materials. No differences were observed from Time 1 to Time 2 for chemotherapy, 
radiation, stem cell transplantation, or clinical trials. 
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Table 8 
Mixed 2 (groups) x 2 (time) x 6 (treatment options) ANOVA, Treatment Ratings for groups 
across time 
______________________________________________________________________________ 
Source                                                 df                                          F                                            p 
______________________________________________________________________________ 
 
Within 
 
Treatment Options1                            3.545                                 4.75                                     <.01 
 
Treatment Options*Group1                3.545                                 .16                                       .948 
 
Error (Treatment) 1                             205.6               MS = 1.94 
______________________________________________________________________________ 
 
Time                                                      1                                       5.81                                    <.05 
 
Time*Group                                          1                                       3.22                                    .078 
 
Error (Time)                                         58                     MS = .528 
______________________________________________________________________________ 
 
Treatment Options*Time1                   3.365                                 3.01                                    <.05 
 
Treatment Options*Time*Group1       3.365                                 1.94                                     .12 
 
Error (Treatment Options*Time) 1      195.17              MS = .817 
______________________________________________________________________________ 
 
Between 
 
Group                                                     1                                     .013                                     .909 
 
Error (Group)                                        58                   MS = .079 
______________________________________________________________________________ 
1 Greenhouse-Geisser correction used
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Table 9 
Estimated marginal means for treatment ratings for groups combined 
______________________________________________________________________________
Treatment option                            Time                Estimated Marginal Mean Rating 
______________________________________________________________________________ 
 
Chemotherapy                                 Time 1                              2.47 
                                                         Time 2                              2.70 
 
Radiation                                         Time 1                              2.82 
                                                         Time 2                              2.80 
 
Biologic therapy*                            Time 1                               2.70 
                                                         Time 2                               3.10 
 
Stem Cell Transplant                       Time 1                               2.45 
                                                         Time 2                               2.42 
 
Watch and Wait*                             Time 1                               2.23 
                                                         Time 2                               2.60 
 
Clinical Trial                                   Time 1                                2.40 
                                                         Time 2                                2.23 
______________________________________________________________________________
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Figure 4. Ratings of treatment preference across time for the guided decision aid group 
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Figure 5. Ratings of treatment preference across time for the comparison group 
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Exploratory Treatment Preference Analysis 2:  Will there be an interaction between treatment 
options, time, and groups for rankings of preference? In other words, will rankings of preference 
for treatment options change across time for the guided decision aid group and/or the comparison 
group? 
 Participants were asked to rank order the six treatment options from 1 to 6 (1 = best 
treatment option and 6 = worst treatment option) before and after reading either the guided 
decision aid or comparison decision aid. The question was whether the guided decision aid and 
comparison decision aid would influence the ranking of treatment options across time. We 
examined this using a Mixed 2 (groups) X 2 (time) X 6 (treatment options) ANOVA (full results 
presented in Table 10). Mauchlys test of sphericity revealed that the assumption of sphericity 
was violated for the main effects of Treatment Options [χ2(14) = 57.0, p < .001] and Treatment 
Options x Time [χ2 (14) = 46.4, p < .001].  Degrees of freedom were corrected using the 
Greenhouse-Geisser correction (ε = 3.55 for Treatment Options and 3.76 for Treatment Options 
x Time). Means for rankings of treatments for each group are presented in Figures 6 and 7. 
 There was a significant main effect for treatment options, [F(3.55, 206.1) = 11.3, p < 
.001; Table 10], suggesting that the treatment options differed in how highly they were ranked. 
However, there was not a significant interaction between treatment options and groups [F(3.55, 
206.1) = .16, p = .94]. This suggested that groups did not differ in overall rankings of treatments. 
Also, there was not a significant main effect for time [F(1, 58) = 1.0, p = .32], and there was not 
a significant interaction between time and groups [F(1, 58) = 1.0, p = .32]. Thus, rankings of 
treatment options did not differ across time, and groups did not differ across time. However, a 
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significant interaction was found between treatment options and time [F(3.76, 218.2) = 5.32, p < 
.01]. Thus, treatments options were ranked differently across time. 
 There was a significant three-way interaction between treatment options, time, and 
groups [F(3.76, 218.2) = 4.11, p < .05]. Thus, groups differed in rankings of treatment options 
across time. Analyses of simple interactions and simple main effects were conducted to further 
explore this interaction. Keppel (1991) suggests conducting analyses that are most consistent 
with the questions one is interested in answering with the data. The research questions focused 
on whether rankings of treatment options changed across time for each group; thus, separate 
repeated-measure ANOVAs were conducted to analyze simple interactions for each group. A 
significant interaction was not found between time and treatment options for the guided decision 
aid group [F(3.86, 111.79) = 2.099, p = .088, η2 = .067]. Thus, there was no change in rankings 
of treatment options across time for the guided decision aid group. However, there was a 
significant interaction between time and treatment options for the comparison group [F(3.23, 
93.68) = 7.59, p < .001, η2 = .207]. This indicates that rankings of treatment options changed 
across time for the comparison group. Analyses of simple simple effects were conducted to 
follow this significant interaction using Least Significant Difference test with a Bonferroni 
adjustment for alpha (Keppel, 1991). For the comparison group, rankings for preference of 
biologic therapy decreased following use of the comparison decision aid (p < .05). See Table 11 
for estimated marginal means for both groups. Rankings of stem cell transplant increased (p < 
.01). Rankings of watch and wait decreased (p < .001). Since lower rankings indicate higher 
preference for the treatment options, preference for biologic therapy and watch and wait 
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increased; whereas, preference for stem cell transplant decreased for the comparison group 
following use of the comparison decision aid. 
Table 10 
Mixed 2 (groups) x 2 (time) x 2 (treatment options) ANOVA, Treatment Rankings for groups 
across time 
______________________________________________________________________________ 
Source                                                   df                                          F                                          p 
______________________________________________________________________________ 
 
Treatment Options1                              3.55                                  11.26                                   <.001 
 
Treatment Options*Group1                  3.55                                 .162                                        .944 
 
Error (Treatment) 1                               206.1               MS = 6.11 
______________________________________________________________________________ 
 
Time                                                       1                                       1.00                                     .321 
 
Time*Group                                           1                                       1.00                                     .321 
 
Error (Time)                                          58                     MS = .022 
______________________________________________________________________________ 
 
Treatment Options*Time1                    3.76                                   5.32                                    <.01 
 
Treatment Options*Time*Group1        3.76                                   4.11                                    <.05 
 
Error (Treatment Options*Time) 1       218.15              MS = 2.31 
______________________________________________________________________________ 
 
Between 
 
Group                                                     1                                     1.00                                     .321 
 
Error (Group)                                        58                   MS = .004 
______________________________________________________________________________ 
1 Greenhouse-Geisser correction used 
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Table 11 
Estimated marginal means for treatment rankings for each group 
______________________________________________________________________________ 
Group                                      Treatment option         Time          Estimated Marginal Mean Rank 
______________________________________________________________________________ 
 
Decision Aid Group                Chemotherapy             Time 1                      3.40 
                                                                                     Time 2                      2.63 
 
                                                 Radiation                     Time 1                      2.90 
                                                                                      Time 2                      2.87 
 
                                                 Biologic therapy          Time 1                      3.17 
                                                                                      Time 2                      2.83 
 
                                                 Stem Cell Transplant   Time 1                      3.33 
                                                                                      Time 2                      3.87 
 
                                                 Watch and Wait           Time 1                      4.07 
                                                                                      Time 2                      4.13 
 
                                                  Clinical Trial               Time 1                      4.13 
                                                                                      Time 2                      4.67 
______________________________________________________________________________ 
Comparison Group                  Chemotherapy             Time 1                       2.73 
                                                                                     Time 2                       3.33 
 
                                                 Radiation                     Time 1                       2.93 
                                                                                      Time 2                      3.10 
 
                                                 Biologic therapy*         Time 1                      3.17 
                                                                                      Time 2                      2.50 
 
                                                 Stem Cell Transplant*  Time 1                      3.20 
                                                                                      Time 2                      4.13 
 
                                                 Watch and Wait*         Time 1                      4.63 
                                                                                      Time 2                      3.10 
 
                                                  Clinical Trial               Time 1                      4.33 
                                                                                      Time 2                      4.70 
______________________________________________________________________________ 
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Figure 6. Rankings of treatment preference across time for the guided decision aid group 
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Figure 7. Rankings of treatment preference across time for the comparison group 
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Exploratory Predictor Question 1: How much variance can be accounted for in predicting change 
in satisfaction with decision using the following predictor variables: age, gender, education, 
anxiety, depression, need for cognition, and monitoring? 
In this section, we explored individual variables that could potentially predict change in 
satisfaction with decision in the guided decision aid group while controlling for shared variance 
between predictors. A Stepwise Multiple Regression analysis revealed that for the decision aid 
group, age was the only significant predictor of change in Satisfaction with Decision (β = -.299, 
R2 = .089, p < .05; Table 12). A Multiple Regression analysis was also conducted to predict 
residualized change scores for Satisfaction with Decision to control for the initial satisfaction 
values. None of the variables were significant predictors of change in Satisfaction with Decision 
(see Table 13). This suggests that although age was a predictor of raw change in Satisfaction 
with Decision, this finding may have been influenced by the initial satisfaction score.1 Pearson 
Product Moment Correlation coefficients for predictor and criterion variables are presented in 
Appendix O. Mean values of continuous predictor variables are presented in Appendix P.
 68
Table 12 
Stepwise multiple regression, predictors of change in Satisfaction with Decision 
______________________________________________________________________________ 
                                                           β                                t score                                    p 
______________________________________________________________________________ 
  
Constant    B = 11.922 (SE = 3.4)                                         3.52                                  .001 
 
Variables Entered 
 
Age                                                 -.299                             -2.386                                 <.05* 
 
R2 = .089, p < .05* 
 
 
Excluded Variables 
 
Need for Cognition                        -.062                             -.487                                    .628 
 
Monitoring/Blunting                      .107                              .825                                     .413 
 
STAI                                              -.052                             -.398                                    .692 
 
CES-D                                           -.125                             -1.00                                    .321 
 
Gender                                           -.155                             -1.213                                  .230 
 
Education                                      -.023                              -.180                                   .024 
______________________________________________________________________________ 
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Table 13   
Stepwise multiple regression, predictors of residualized change in Satisfaction with Decision 
______________________________________________________________________________ 
                                                           β                                t score                                    p 
______________________________________________________________________________ 
  
Constant    B = .356 (SE = 1.856)                                       .192                                     .849 
 
Age                                                 -.020                             -.113                                   .895 
 
Need for Cognition                        -.073                              -.481                                   .633 
 
Monitoring/Blunting                      .041                               .285                                    .776 
 
STAI                                              -.118                              -.610                                   .545 
 
CES-D                                             .193                              1.03                                    .306 
 
Gender                                            -.080                             -.486                                   .629 
 
Education                                        .106                              .772                                    .444 
______________________________________________________________________________ 
R2 = .053, p = .888 
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Exploratory Predictor Question 2: How much variance can be accounted for in predicting change 
in decisional conflict using the following predictor variables: age, gender, education, anxiety, 
depression, need for cognition, and monitoring? 
 In this section, we explored individual variables that could potentially predict change in 
decisional conflict in the guided decision aid group while controlling for shared variance 
between predictors. A Stepwise Multiple Regression analysis revealed that for the decision aid 
group, age was the only significant predictor of change in Decisional Conflict (β = .529, R2 = 
.280, p < .001; Table 14). When a Stepwise Multiple Regression analysis was conducted using 
residualized change scores for Decisional Conflict as the criterion variable, age was a significant 
predictor (β = .377, R2 = .142, p < .01; Table 15). Thus, it appears that age accounted for a 
moderate amount of variance in predicting change in decisional conflict. Pearson Product 
Moment Correlation coefficients for predictor and criterion variables are presented in Appendix 
O. Mean values of continuous predictor variables are presented in Appendix P. 
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Table 14 
Stepwise multiple regression, predictors of change in Decisional Conflict 
______________________________________________________________________________ 
                                                           β                                t score                                    p 
______________________________________________________________________________ 
 
Constant    B = -31.004 (SE = 4.79)                                    -6.478                                  <.001 
 
Variables Entered 
 
Age                                                 .529                               4.743                                  <.001* 
 
R2 = .280, p < .001* 
 
 
Excluded Variables 
 
Need for Cognition                        -.088                              -.784                                   .436 
 
Monitoring/Blunting                      -.211                             -1.876                                  .066 
 
STAI                                              -.075                             -.649                                    .519 
 
CES-D                                           .070                               .622                                     .537 
 
Gender                                           .040                               .344                                     .732 
 
Education                                      -.020                              -.179                                    -.024 
_____________________________________________________________________________ 
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Table 15  
 
Stepwise multiple regression, predictors of residualized change in Decisional Conflict 
______________________________________________________________________________ 
                                                           β                                t score                                    p 
______________________________________________________________________________ 
  
Constant    B = -2.331 (SE = .761)                                     -3.063                                  .003 
 
Variables Entered 
 
Age                                                 .377                               3.102                                  <.01 
 
R2 = .142, p < .01* 
 
 
Excluded Variables 
 
Need for Cognition                         .009                              .076                                     .940 
 
Monitoring/Blunting                      -.168                            -1.354                                    .181 
 
STAI                                              -.050                              -.395                                     .695 
 
CES-D                                           -.140                             -1.151                                    .255 
 
Gender                                            .006                               .049                                      .961 
 
Education                                       -.162                            -1.345                                     .184 
______________________________________________________________________________ 
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Exploratory Predictor Question 3:  How much variance can be accounted for in predicting 
change in knowledge using the following predictor variables: reading time and time spent 
making decision? 
 We also explored the extent to which reading time and time until the decision predicted 
knowledge gained about follicular lymphoma. A Stepwise Multiple Regression analysis revealed 
that time spent reading the guided decision aid was the only significant predictor of change in 
Knowledge for the decision aid group (β = .424, R2 = .072, p < .05; Table 16).2 Mean values and 
Pearson Product Moment Correlation coefficients for predictor and criterion variables are 
presented in Appendix Q. 
 
Table 16 
Stepwise multiple regression, predictors of change in Knowledge 
______________________________________________________________________________ 
                                                           β                                t score                                    p 
______________________________________________________________________________ 
 
Constant     (B = 2.57, SE = 1.09)                                       2.36                                     .022 
 
Variable Entered 
 
Time reading materials                    .269                            2.13                                    <.05* 
 
R2 = .072, p < .05* 
 
Variable Removed 
 
Time until decision                          -.113                           -.777                                    .440                            
______________________________________________________________________________ 
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What was most/least helpful about the decision aid? 
 
After the study, participants in the guided decision aid group were asked to complete the 
Opinion of the Decision Aid questionnaire to determine what information they felt was most 
important in making their decision. Participants answers to this questionnaire are listed in 
Appendix R. Many participants felt that the most helpful parts of the decision aid were the 
descriptions of treatments and the lists of pros and cons. There was no evident frequent response 
when asked what was least helpful about the decision aid. A few people mentioned that the 
reference section was the least helpful. Others offered suggestions for more information to 
include such as more information about survival time. 
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Discussion 
 The following section describes the goals of the current study, discusses the findings, and 
relates the findings to the relevant literature. The implications of this study as well as the 
limitations and future directions for this research are also discussed. 
 Several studies have demonstrated that the use of a decision aid in medical decision-
making for cancer can improve satisfaction with decision, decrease decisional conflict, and 
increase knowledge about the medical condition and treatment options (e.g., Brundage, 2001; 
Street et al., 1995; Whelan et al., 2003). The goal of the present study was to create and evaluate 
a guided decision aid for treatment selection in follicular non-Hodgkin's Lymphoma, which is a 
form of cancer with multiple complex treatment options (Ansell & Armitage, 2005).  
This study was conducted in two phases. The first phase involved the creation of the 
guided decision aid. Patients were asked to identify information they felt would be important to 
include and to evaluate and revise the final draft of the decision aid according to their 
preferences. Then, the guided decision aid, and comparison decision aid, were evaluated and 
compared using a non-patient sample. The participants were asked to make a decision about 
treatment as if they were a patient, before and after reading the guided decision aid or 
comparison decision aid. Changes in satisfaction with decision, decisional conflict, knowledge, 
ratings of treatment preferences, and rankings of treatment preferences were evaluated at the 
time of each decision. We expected satisfaction with decision would increase, decisional conflict 
would decrease, and knowledge would increase following use of the decision aid, and that these 
changes would be greater for the guided decision aid than the comparison decision aid. We also 
expected that ratings and rankings of treatment preference would change more for the guided 
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decision aid group than for the comparison group. Several individual difference variables were 
explored as predictors of decision aid effectiveness. Thus, exploratory analyses were performed 
with the decision aid group to examine the extent to which age, gender, depression, anxiety, 
monitoring/blunting, need for cognition, and education would predict a change in decisional 
conflict or satisfaction with decision. Additionally, we explored whether time spent reading the 
decision aid, or time spent making the decision would predict change in knowledge in the guided 
decision aid group. 
 The following section is a review of the findings from this study and a discussion of 
implications of these findings in light of the relevant literature. 
Satisfaction with Decision, The primary hypotheses driving this research related to the 
effectiveness of the guided decision aid for follicular Lymphoma. The first hypothesis, that 
following use of the materials, satisfaction with decision would increase more for the guided 
decision aid group than for the comparison group, was not supported. The results showed that 
satisfaction with decision increased following use of the guided decision aid. However, contrary 
to previous findings (Molenaar et al., 2001; Sebban et al., 1995; Whelan et al., 2003; Whelan et 
al., 2004), the results revealed no difference in the change in satisfaction between the decision 
aid and comparison groups. Thus, it appears that both the guided decision aid and comparison 
decision aid were equally effective in increasing satisfaction with decision.   
There are several possible reasons why no difference in results was found between the 
guided decision aid group and comparison group. Few studies in the cancer decision aid 
literature have examined satisfaction with decision. Several of the previous studies compared a 
decision aid to medical consultations without giving participants additional reading materials 
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(Molenaar et al., 2001; Whelan et al., 2003; Whelan et al., 2004). The authors did not clearly 
state how much information was conveyed to the participants during these consultations. Only 
one study compared a decision aid group to a group that received a pamphlet (Sebban et al., 
1995). These authors also found that the decision aid group had significantly higher satisfaction 
with decision than the comparison group. The authors stated that the pamphlet was a shortened 
version of the decision aid, but they did not clearly state how much information was included in 
the pamphlet. If the pamphlet included very minimal information, this could have accounted for 
the difference in satisfaction between groups. 
Additionally, several of the previous studies in the cancer decision aid literature used 
patient samples (Molenaar et al., 2001; Whelan et al., 2003; Whelan et al., 2004). It is possible 
that no difference was found between the two groups because non-patients were used in the 
current study. Since patients assisted in the creation of the guided decision aid for the present 
study, the decision aid contained information identified as important to a patient sample. For our 
non-patient sample, the information offered in the comparison decision aid may have been seen 
as sufficient for making a decision about treatment in the patient vignette, whereas patients may 
have found the additional information and exercises of the guided decision aid more helpful than 
the comparison decision aid. Patients may have found the decisional context more salient and the 
information in the aid more personally relevant and important. Thus, patients may have been 
more satisfied with their decisions due to the more comprehensive and personally relevant 
information in the guided decision aid. Only one study in the cancer decision aid literature used a 
non-patient sample to examine satisfaction with decision (Sebban et al.,, 1995). It is difficult to 
compare the Sebban et al. (1995) sample to the sample in the current study, since the authors in 
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the previous study did not list many demographic variables. The Sebban et al. (1995) sample 
included younger participants than the current study, but it is unclear whether this might account 
for the different findings between this and the current study.  
The comparison decision aid was created using less information to make it similar to a 
pamphlet that a patient might find in the physicians office; however, the same material was used 
in the creation of the pamphlet. This method was used because there was no pamphlet available 
for follicular lymphoma that we could use for comparison. If there had been a pamphlet available 
for use for the comparison group, there may have been a difference between the groups, as the 
pamphlet would have likely offered somewhat different information than that presented in the 
decision aid. A review of other pamphlets for lymphomas revealed that most pamphlets offered 
different information, different explanations of treatments, and different material. 
Decision Conflict. The second hypothesis, that following use of the materials, decisional 
conflict would decrease more for the guided decision aid group than for the comparison group, 
was not supported. Few studies have examined decisional conflict among users of cancer 
decision aids. The present results showed that decisional conflict decreased following use of the 
guided decision aid, which was similar to findings in previous studies of cancer decision aids 
(Brundage et al., 2000; Brundage et al., 2001; Fiset et al., 2000). However, there was no 
difference in decisional conflict decrease between the guided decision aid and comparison 
groups. This finding is contrary to results of Whelan et al. (2004), but supports the findings of 
Goel et al. (2001) in that there was not a significant difference in decisional conflict between the 
decision aid group and a group that received a pamphlet. The Whelan et al. (2004) study used a 
decision aid in comparison to medical consultations and found that the decision aid group had 
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less decisional conflict than medical consultation groups. Whelan et al. (2004) did not clearly 
describe the nature and amount of information conveyed during the medical consultations. If the 
information during these consultations was minimal, this may have accounted for differences in 
decisional conflict between groups.  
Another potential reason for the difference in findings between the Whelan et al. (2004) 
study and the present study is that the Whelan et al. study asked participants to choose between 
two treatment options, while the current study asked participants to choose between six. Previous 
research suggests having many options results in more difficulty making selections (Iyengar & 
Lepper, 2000). Thus, participants in the current study may have been overwhelmed with the 
number of options in the decision aid, which may have prevented a larger decrease in decisional 
conflict. 
A possible reason for the difference in findings between the current study and Whelan et 
al. (2004) is that the Whelan et al. study used a patient sample, while the present study used a 
non-patient sample. Again, patients may have found the decisional context more salient and the 
information in the aid more personally relevant and important. Thus, patients may have 
experienced less decisional conflict due to the more comprehensive and personally relevant 
information in the decision aid.  
Knowledge. The third hypothesis, that knowledge would increase more for the guided 
decision aid group than for the comparison group following use of the materials, was not 
supported. The results showed that knowledge increased for both groups following use of the 
decision aid, which is consistent with previous studies (Brundage et al., 2000; Brundage et al., 
2001; Schapira et al., 1997). However, knowledge did not increase more for the guided decision 
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aid group than the comparison group, which is contrary to some previous findings in the cancer 
decision aid literature (Whelan et al., 2003; Whelan et al., 2004), but confirms findings from 
other studies in the cancer decision aid literature (Chapman et al., 1995; Goel et al., 2001; 
Holmes-Rovner et al., 2005; Street et al., 1995).   
One possible reason for the inconsistency in the previous studies of knowledge 
acquisition is that several previous studies did not assess baseline knowledge (Chapman et al., 
1995; Goel et al., 2001; Holmes-Rovner et al., 2005; Whelan et al., 2003; Whelan et al., 2004). 
Thus, it is not known how well the groups would have performed on the knowledge measure 
before using the decision aid or reading the pamphlet, and it is not known whether knowledge 
increased due to the materials. The present study assessed baseline knowledge to ensure an 
accurate measure of knowledge acquired from the materials. 
Some of the previous studies (Whelan et al., 2003; Whelan et al., 2004) compared 
knowledge gained after using a decision aid to knowledge gained in medical consultations. These 
studies found that the decision aid group retained more knowledge than the medical consultation 
groups. Previous studies that did not find a difference between the decision aid and comparison 
group, used a pamphlet as a comparison (Chapman et al., 1995; Goel et al., 2001; Holmes-
Rovner et al., 2005). Studies that used medical consultations as the comparison group did not 
clearly describe the quantity of information conveyed during the medical consultations. If the 
information during these consultations was minimal, this may have accounted for differences in 
knowledge acquisition between groups.  
Treatment Preferences. In addition to examining effectiveness of the decision aid, we 
were also interested in whether the decision aid might affect preference for the treatment options. 
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The current study explored the question of whether use of the guided decision aid or comparison 
decision aid would result in changes in ratings of treatment preference in the non-patient sample. 
The results revealed that pre-post ratings of treatment preference changed across time for both 
groups and differed between treatment options for both groups; however, the groups did not rate 
the treatment preferences differently. The results confirm the findings of Molenaar et al. (2001), 
who found that treatment choices did not differ between a decision aid group and comparison 
group. However, the results conflict with the findings of Sebban et al. (1995). Sebban et al. 
found that treatment choices differed in a non-patient sample between the decision aid group and 
a group that received a shorter version of the decision aid. As discussed above, it is possible that 
the reason we did not see a difference between groups was that we did not use a patient sample. 
Participants in the present study were asked to make a decision about treatment relatively soon 
after using the guided decision aid and comparison decision aid. It is likely that patients who are 
not making decisions in the context of an experiment may take more time to deliberate over the 
treatment options and weigh the risks and benefits over a much longer period of time. It is 
possible that the risks and benefits presented in the decision aid might have yielded a greater 
change in treatment preference over time. Molenaar et al. (2001) utilized a patient sample and 
physician consults for the comparison group. The current study is most similar to the Sebban et 
al. (1995) study because of the use of a non-patient sample, and a pamphlet for the comparison 
group. Thus, it is curious that the findings of this study were not consistent with Sebban et al. 
(1995). 
The nature of the interaction between treatment options and time was examined, 
revealing that preference ratings of biologic therapy, and watch and wait, increased over time. 
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This was consistent with the expectations in that ratings of these lesser-known treatment options 
were expected to increase following use of the informational materials. Preference for the lesser-
known treatment options likely increased because patients rated them lower at first due to 
unfamiliarity, and then rated them higher after reading the information and learning about the 
benefits of these treatment options. Although the information presented in the guided decision 
aid and comparison decision aid was objective, it is also possible that biologic therapy and watch 
and wait were perceived as more preferable following use of the materials. The materials may 
have discussed positive aspects of these options that were not considered by the participants 
before reading the materials. 
Rankings of Treatment Preference. The question of whether use of the guided decision 
aid or comparison decision aid would result in changes in rankings of treatment preference in the 
non-patient sample was explored. The results were consistent with Sebban et al. (1995) in that 
the groups differed in treatment preferences. However, contrary to expectations, only the 
comparison group showed significantly different rankings for treatment options across time. It is 
unclear why there was more change in rankings in the comparison group.  
One speculation about why there was not a change in treatment rankings across time for 
the decision aid group was that these participants might have been presented with more 
information than was possible to process, or that they were willing to process, in a short period 
of time. Although knowledge of the materials increased following use of the guided decision aid, 
this does not necessarily mean that participants were able or willing to process the information 
well enough to incorporate it into a final decision in which they felt confident. Previous research 
suggests that when faced with many options from which to choose, people have more difficulty 
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making selections (Iyengar & Lepper, 2000). Since these participants made decisions about 
treatment options in only a few minutes, the detailed information about risks and benefits 
presented in the decision aid may have been too much information about too many treatment 
options in such a short period of time. Thus, participants may have been more likely to choose 
the same treatments after reading the decision aid that they chose before because the information 
about the treatment options was too much to process. Those in the comparison group read less 
information about the treatment options, and thus changed their treatment selection after 
processing the information. Perhaps the amount of information presented in the guided decision 
aid was too much or too tedious to process in a short period of time. 
When the nature of the change in rankings of preference for treatment options across time 
was examined for the comparison group, preference for biologic therapy increased, stem cell 
transplantation decreased, and watch and rate increased. Since lower rankings indicate higher 
preference, preference increased for biologic therapy, and watch and wait, while preference 
decreased for stem cell transplantation. Although we did not see a change in rankings of 
treatment options across time for the guided decision aid group, the results from the comparison 
group were consistent with our expectations in that lesser-known treatments were ranked as more 
preferable following use of the reading material. However, stem cell transplantation, which could 
be considered a less well-known treatment option, was ranked less preferable following use of 
the comparison decision aid. A conversation with one of the participants following this study 
may shed some light on this finding. This participant told the researcher that several years before 
this study, a teenager in Winona, MN, the town from where participants were drawn, was 
diagnosed with Hodgkins Lymphoma, and the town conducted a fundraiser to raise money for 
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an autologous stem cell transplant for him. Hodgkins disease can often be put into remission 
with a stem cell transplant (Evens et al., 2007), and as such, this patient was in remission 
following the transplant. Thus, since Winona is a small town, many of the participants likely 
knew about this success story, and rated stem cell transplant highly before reading the materials. 
After reading the comparison decision aid, participants may have realized that stem cell 
transplantation has many risks associated with it, and then rated it lower. Thus, participants less 
familiar with stem cell transplantation success might have shown results more consistent with 
our expectation of lower initial ratings and higher ratings after reading the information. 
Although there was not a difference between groups in treatment preference that we had 
expected, both groups showed an increase in satisfaction, a decrease in decisional conflict, and 
an increase in knowledge following use of the guided decision aid and comparison decision aid. 
Thus, our findings suggest that regardless of whether use of the reading materials resulted in a 
change in the treatment decision, they increased the satisfaction with decision, decreased 
decisional conflict, and increased knowledge. 
Individual Predictors of Change in Satisfaction with Decision. One of the goals of this 
study was to discover whether individual characteristics predicted effectiveness of the guided 
decision aid. The exploration revealed no significant predictors of change in satisfaction. The 
finding that age did not emerge as a predictor is similar to a finding by Berry et al. (2006), who 
also found that age was not a significant predictor of satisfaction with decision. Anxiety and 
depression may not have emerged as significant predictors because the mean anxiety and 
depression scores in this sample were low and had a restricted range. Cancer patients are more 
likely to experience anxiety and depression (Bock, 2006); therefore, the wider range of anxiety 
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and depression symptoms in a patient sample might have contributed to the prediction of change 
in satisfaction with decision. It was expected that those high in need for cognition, monitoring, 
and education would be associated with an increase in satisfaction with decision. It is unclear 
why need for cognition, monitoring/blunting, and education did not emerge as predictors of 
change in satisfaction with decision. 
Individual Predictors of Change in Decisional Conflict.  The same individual difference 
variables that were explored as predictors of satisfaction were also explored as predictors of 
decisional conflict. Age contributed to the prediction of change in decisional conflict. As age 
decreased, decisional conflict decreased. Thus, it appeared that the decision aid may have been 
less effective for older individuals. Unfortunately, the relation between age and decisional 
conflict has not been examined in previous studies. One speculation for the current finding is that 
older adults have more difficulty processing the complex information presented in the decision 
aid. Previous research suggests that older adults have more difficulty with decision-making and 
make more inconsistent decisions when information related to the decision is complex (Finucane 
& Mertz, 2005). If older adults experienced more difficulty processing the information, they 
likely did not feel confident in the choice they made following use of the materials. Thus, the 
older adults did not show a decrease in decisional conflict. 
Another possible explanation for the current finding is that older adults preferred to be 
more passive in the decision-making process and preferred to receive less information (Cassileth 
et al., 1980; Pinquart & Duberstein, 2004). Thus, older adults may not have shown a decrease in 
decisional conflict because they would have preferred to be less involved in the decision-making 
process. It is possible that despite the fact that they were making more informed decisions after 
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using the decision aid, older adults may have felt more uncomfortable with making a decision 
about treatment. Thus, when they made a decision in this study, they still felt uncertain about 
their decision after reading the decision aid. 
Once again, anxiety and depression may not have emerged as significant predictors of 
change in satisfaction with decision because the mean anxiety and depression scores were in this 
sample were low and had a restricted range. As discussed previously, cancer patients are more 
likely to experience anxiety and depression (Bock, 2006); therefore, the wider range of anxiety 
and depression symptoms in a patient sample might have predicted change in decisional conflict. 
It was also thought that those high in need for cognition and monitoring would be associated 
with an increase in satisfaction with decision. It is unclear why need for cognition and 
monitoring/blunting did not emerge as predictors of change in satisfaction with decision. 
 Individual Predictors of Change in Knowledge. The extent to which the amount of time 
the individuals spent with the decision aid might predict the amount of knowledge gained was 
examined. Time spent reading the decision aid predicted knowledge acquired. The results 
suggest that those who took more time and care in reading the decision aid gained more 
knowledge. This finding suggests that it may be beneficial for patients to read slowly and 
thoroughly to gain the most knowledge about the information. 
 Most Helpful/Least Helpful Aspects of the Decision Aid. Participants reported that the 
most helpful aspects of the guided decision aid were the descriptions of treatment options and the 
list of pros and cons. There was no apparent "least helpful" aspect of the decision aid.  
Overall, it appeared that the guided decision aid was well-received by participants and the 
most helpful sections identified were the lists of risks and benefits and treatment descriptions. 
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The item seen as least helpful was the reference section, which was a necessary part to include 
credit to sources, but was not necessary for the decision-making process. However, this section 
might be more helpful to patients who wish to seek other sources of information. When 
examining the answers given by participants, it is not evident that changes need to be made to the 
guided decision aid at this time. 
Limitations 
 As discussed previously, the aim of this study was to add to the cancer decision aid 
literature by adjusting for some of the methodological flaws in previous literature as well as to 
develop a decision aid for the largely ignored and very difficult treatment selection in follicular 
NHL. However, the current study was not without its own areas in need of improvement. 
 There were some drawbacks to using a non-patient sample. Using a non-patient sample 
did not allow evaluation of all of the potential benefits of the guided decision aid. Since patients 
assisted in the development of the decision aid, the contents were likely more beneficial for a 
patient sample, and may have explained why we did not see a difference in effectiveness 
between the guided decision aid group and the comparison group. Additionally, there were 
components of the guided decision aid that were designed to facilitate the physician/patient 
relationship (i.e., questions to ask your doctor and sources for further information). Evaluating 
the decision aid in a non-patient sample did not allow us to evaluate the effectiveness of these 
portions of the decision aid. Finally, participants in this study were asked to make a treatment 
decision in a very short period of time. Patients would likely take hours or days to make such a 
decision. Thus, generalizability of the present findings to cancer patients may be questionable. 
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 The sample used for this study was not representative of the general population. All of 
the participants were Caucasian, which means that we cannot necessarily extend the results of 
this study to other races. The patients in this sample also had low scores on the measures of 
depression and anxiety, which likely decreased our ability to evaluate the effectiveness of this 
decision aid in more depressed and anxious individuals. The restricted range in these measures 
would have decreased our ability to predict change in decisional conflict and satisfaction with 
decision. Cancer patients often experience symptoms of depression and anxiety (Block, 2006), 
and we cannot generalize the effectiveness of the decision aid to these individuals. 
 Sample size may have been a limiting factor in power for the multiple regression analyses 
conducted for the prediction of decision aid effectiveness. Since the pre-post analyses of decision 
aid effectiveness were considered the primary hypotheses, the sample size was based on 
adequate power for those analyses. Multiple regression analyses require 10 to 15 participants per 
predictor (Field, 2000). Our analyses included only about 4-5 participants per predictor. Thus, 
more significant predictors of effectiveness may have emerged with a larger sample size. 
Future Directions 
 There are several possible directions in which to take this area of research. A logical 
next-step for the current study would be to evaluate the guided decision aid in a patient sample. 
As discussed above, since patients contributed to the creation of the guided decision aid, patients 
may have found the guided decision aid to be more effective than the comparison decision aid. 
Since the guided decision aid was designed for use by patients, a patient sample would give a 
better indication of the benefit of the decision aid.  
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 There are some other possible variations that could be of use in examining the 
effectiveness of this aid. For example, the current study evaluated the guided decision aid against 
a shortened version of the guided decision aid. A future study could add another comparison 
group that would receive irrelevant information (e.g., a decision aid targeted toward a different 
medical dilemma). This group would offer a comparison to see whether simply making the 
decision about treatment twice would result in higher satisfaction with decision and lower 
decisional conflict after the second decision. 
 A future study could examine changes in treatment selection over time. Participants in 
this study made a decision about treatment in a few minutes; however, patients would likely 
deliberate over treatment selection for several days. Thus, patients using the decision aid over 
time would likely add to the lists of risks and benefits and change treatment preference over time 
as they incorporate information from oncologists and significant others. This would support 
findings by Feldman-Stewart et al. (2001) that revealed several changes in treatment preference 
while using a decision aid. 
Additionally, it may be beneficial to examine whether individual characteristics influence 
the effectiveness of the decision aid in a patient sample. A patient sample would likely be more 
representative of the patient population and would likely have higher scores in characteristics 
such as depression and anxiety, as cancer patients commonly experience anxious and depressive 
symptoms (Block, 2006). It could also be beneficial to evaluate whether other characteristics 
(e.g., race, SES) may be predictive of effectiveness of the decision aid to continue to examine 
types of individuals for which the decision aid would be most effective.  
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As Kennedy (2003) has suggested, future studies should focus on whether decision aids 
help participants in making decisions consistent with their values. This has been largely 
neglected in the literature. The decision aid in the current study led patients through value 
clarification exercises to assist in the decision-making process. A future study could focus on 
whether the decisions made by patients are consistent with their values. 
Finally, there are several areas within medical decision-making for which decision aids 
have not yet been created and/or evaluated. There is need for more decision aids within the blood 
cancers. For example, a decision aid has not yet been created for patients with acute 
myelogenous leukemia, who must decide whether to undergo a stem cell transplant after a 
relapse of the disease (Mathews & DiPersio, 2004). There is also a need for decision aids outside 
the cancer literature. For instance, a decision aid has not yet been created to help patients decide 
whether to undergo bariatric surgery for obesity (Brethauer et al, 2006). 
Conclusions 
 The goal of the current study was to create and evaluate a guided decision aid for 
treatment selection in follicular non-Hodgkins lymphoma. Additionally, we examined whether 
individual characteristics predicted the effectiveness of the decision aid. This study involved 
patients in the creation of the guided decision aid and in evaluation of the utility of the final 
guided decision aid product.  
 The results of this study showed that in a non-patient sample, the guided decision aid was 
effective in improving satisfaction with decision, decisional conflict, and knowledge; however, 
the guided decision aid was not more effective than a comparison decision aid. The decision aid 
appeared to be more effective for younger adults. Although some evidence of effectiveness of 
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the decision aid was apparent in this study, there were some drawbacks to using a non-patient 
sample that may have prevented the examination of the full potential of the guided decision aid. 
Further studies should focus on the evaluation of this guided decision aid in a follicular NHL 
patient sample, examination of other potential individual characteristics to predict effectiveness 
of decision aids, and evaluation of decision aids for other areas of difficulty in medical decision-
making. 
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Footnotes 
1 Analyses of normality revealed that monitoring/blunting and CES-D were both positively 
skewed. The same multiple regression analyses were conducted using log transformations of 
monitoring/blunting and CES-D, which corrected the positive skew. These analyses revealed 
the same results as those presented. 
2 The multiple regression was also conducted using the residualized change score for knowledge. 
The results of this analysis were the same as those presented. 
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Purpose of the Decision Aid 
 
One purpose of this decision aid is to offer information 
about the lymphatic system, Follicular non-Hodgkins 
Lymphoma, and treatment options for Follicular non-
Hodgkins Lymphoma. Another purpose of this decision 
aid is to help patients make decisions about which 
treatment options may be best for them. 
 
 
 
What You Will Learn 
 
• The anatomy and function of the lymphatic 
system. 
 
• Symptoms of Follicular non-Hodgkins Lymphoma. 
 
• Procedures of treatment options for Follicular non-
Hodgkins Lymphoma. 
 
• Risks and benefits of treatment options. 
 
 
 
 
 
 
 
 
 
 
 
The Lymphatic System 
 
 
The lymphatic system consists of several body parts 
including: 
• spleen 
• thymus 
• tonsils 
• bone marrow 
• lymph nodes (These are the size of a bean and 
are distributed throughout the body. Clusters of 
lymph nodes are found in the armpits, abdomen, 
groin, pelvis, collarbone area, and neck.)3,4 
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The Lymphatic System 
 
What does the lymphatic system do?     
 
 
! The lymphatic system includes vessels that 
transport fluids throughout the body. A fluid called 
lymph is circulated throughout the lymphatic 
system. This fluid contains white blood cells, which 
are also called lymphocytes. These lymphocytes 
are created in the bone marrow and mature in the 
thymus. They are important in the bodys ability to 
fight infection. 
 
! The spleen and the lymph nodes are filters of the 
lymph fluid. 
 
! When your body is fighting an infection such as 
from bacteria or viruses, the lymph nodes will 
swell with lymphocytes that will target and destroy 
these unwanted organisms in the body.3,4,5 
 
 
 
 
 
 
 
 
 
The Lymphomas 
 
Almost all cells in the human body have the ability to 
divide to produce new cells that can replace the cells that 
die. However, cancer results from a defect within a cell 
that causes the cell to continue to divide faster than the 
rate of cell death. These cancerous cells inhibit the 
growth and survival of normal cells.6  
 
The lymphomas are cancers of the lymphocytes. 
Lymphomas are divided into Hodgkins Lymphoma and 
non-Hodgkins Lymphoma. Non-Hodgkins Lymphoma is 
the most common type of lymphoma. 
 
Non-Hodgkins Lymphoma can be categorized in several 
ways:2,7,8 
By grade: 
  Indolent or Low Grade (slow growing) 
  Intermediate Grade (moderate growth rate) 
  Aggressive or High Grade (fast growing) 
 By stage: 
  Stage I: lymphoma detected in one lymph 
node 
Stage II: lymphoma detected in two or more 
lymph nodes near each other 
Stage III: lymphoma detected in several 
lymph nodes far apart 
Stage IV: widespread involvement of lymph 
nodes as well as organs such as liver, 
lungs, or bone 
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What is Follicular non-Hodgkins Lymphoma? 
 
Follicular Lymphoma is an Indolent (Low Grade) lymphoma. It 
is the second most common type of non- Hodgkins 
lymphoma.9 
 
Follicular Lymphoma is a slow-growing cancer of specific kinds 
of lymphocytes called B-cells.10 These cancer cells are 
grouped in clusters, which are called follicles, in the lymph 
nodes. 
 
For patients diagnosed with Follicular Lymphoma, especially 
those in which the disease is more widespread than Stage I, 
the disease may be considered incurable. This means that 
even after treatment, the disease can be expected to remain 
dormant in the body and may recur. More aggressive 
treatment may lengthen the amount of time between 
recurrences.9,11 
 
With new and better treatment options available, the length of 
survival for patients with follicular lymphoma has been 
increasing over the years.12 
 
Symptoms of follicular lymphoma can be difficult to identify 
and thus, most patients present with advanced-stage 
disease.10 
 
Possible symptoms include: 
• Fever 
• Fatigue 
• Itchy skin 
• Drenching night sweats 
• Unexplained weight loss 
• Pain in chest, bones, or abdomen 
• Painless swelling of lymph nodes 
Treatments for Follicular non-Hodgkins Lymphoma 
 
Treatments available to each patient will depend upon 
several factors including stage of disease, whether 
organs outside of lymph nodes are affected, the 
lymphomas cell type, patient age, and current 
symptoms.2 
 
Current treatment options for follicular lymphoma 
include:2,13 
 
Chemotherapy 
 Radiation 
 Biologic Therapy 
 Stem Cell Transplantation 
 Watch and Wait 
 Clinical Trial 
As of today, there is no consensus among oncologists 
about which treatment option is the best.14 
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Chemotherapy 
 
Chemotherapy is commonly used when a patient is first 
diagnosed, but is also used when the disease recurs.10 
 
Chemotherapy is a drug that is either injected into the 
veins or swallowed orally. Once the drug enters the body, 
it is carried by the blood stream to areas throughout the 
body. These drugs are designed to either kill the cancer 
cells or to stop their ability to multiply.7 
 
Chemotherapy drugs can be used alone, in combination 
with other chemotherapy drugs, or in combination with 
some of the treatments mentioned in the next few 
sections (e.g., radiation, biologic therapy, or stem cell 
transplantation).2,15 Chemotherapy may also be 
combined with steroids. Most chemotherapy treatment 
will require more than one session of treatment. The 
number of sessions will depend on your specific case. 
Each type of chemotherapy can have its own different 
possible risks and benefits. 
 
Examples of common chemotherapy regimens: 
# CHOP: Cyclophosphamide, Doxorubicin, 
Vincristine, Prednisone 
# CVP: Cyclophosphamide, Vincristine, Prednisone 
 
 
 
 
 
 
Chemotherapy 
Benefits  
• Often well-tolerated by patients 
• There are drugs available to counteract some side effects 
such as nausea and low red blood cell count 
• Most side effects will end soon after treatment is finished 
• Chemotherapy is the most commonly used treatment and its 
effects have been well-researched 2,15 
Risks    
• Side effects can include: 
o Hair loss 
o Fatigue 
o Loss of appetite 
o Nausea and vomiting 
o Mouth sores 
o Decreased bone marrow cells 
o Numbness, tingling, burning, or weakness in limbs 
• May have allergic reaction to drugs such as fevers or skin 
rash 
• Reduced lymphocytes from chemotherapy can create 
increased risk for infection 
• Some chemotherapy drugs may damage the heart, bladder, 
or reproductive organs, which could be fatal if these organs 
are already compromised 
• Repeated use of chemotherapy may decrease its 
effectiveness 
• Use of some chemotherapies may increase the risk of other 
cancers in the future 16 
• Use of chemotherapy may not lengthen patient survival 
• Patients with large amounts of cancerous tissue must be 
monitored carefully because toxic chemicals may be 
released when cancer cells are killed, which can be fatal 2,3,15 
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Radiation 
 
Radiation is a treatment that kills lymphoma cells in a 
specific area using high-energy rays.2 The rays work to 
damage the DNA in the lymphoma cells, which can 
cause death of the cancerous cells.15  
 
Before administering radiation, scans will be used to map 
out a specific area on the body for administration of the 
radiation to limit the number of healthy cells that are 
damaged. Treatment usually takes several sessions. 
These sessions typically last about 15 minutes, with 
repeated sessions for several weeks.15 
 
Radiation can be used when the patient has a large area 
of lymphoma cells within a small area of the body, or 
when enlarged lymph nodes are interfering with other 
organs.2 Radiation can be used alone, or it is often used 
in combination with chemotherapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Radiation 
Benefits  
• Treatments are short in duration 
• Most side effects will end soon after treatment is 
finished 
• Will possibly work to quickly control lymphoma at a 
specific site 
• If used with chemotherapy, can reduce the 
number of cycles of chemotherapy required 2,15,17 
 
Risks    
• Side effects often include: 
o Fatigue 
o Decreased appetite 
o Skin irritation near the treated area 
o Bone marrow suppression 
• May have allergic reaction to radiation such as 
fevers or skin rash 
• Reduced lymphocytes from radiation can create 
increased risk for infection 
• Radiation may damage organs near the site of 
treatment 
• This treatment option may not be available for 
cancer that is widespread 
• Radiation may increase the risk of other cancers in 
the future 2,15,17 
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Biologic Therapy 
 
In the human body, antibodies are produced by the immune 
system to help the body know which substances are foreign 
and should be destroyed. Biologic Therapy involves 
treatments that use antibodies to fight the lymphoma.18 
 
Monoclonal Antibody Therapy is a type of biologic therapy in 
which an antibody is injected into the blood. When a 
Monoclonal Antibody is circulated throughout the system, it 
seeks out and destroys lymphoma cells. Monoclonal Antibody 
Therapy is often used in conjunction with chemotherapy.2,17 
 
Radioimmunotherapy is a form of biologic therapy that uses a 
radioactive substance, which is carried to the lymphoma cells 
by monoclonal antibodies. This treatment targets the 
lymphoma cells directly and leaves normal cells intact.2 
 
Examples of Biologic Therapy:17 
# Rituxan: This monoclonal antibody treatment is usually 
injected into the veins every week for about four 
weeks. Each treatment can take anywhere from 4 to 8 
hours, with the first treatments typically taking the 
longest. 
# Zevalin or Bexxar: These radioimmunotherapies are 
actually a form of radiation and are given along with 
Rituxan. It takes seven to nine days to administer. Over 
the course of therapy, body scans are conducted to 
determine how the radiation has distributed throughout 
the body. Radiation is delivered directly to the 
lymphoma cells, which helps to protect normal cells. 
 
 
 
 
Biologic Therapy 
Benefits  
• Medications are available to reduce some side 
effects such as fever and chills 
• Side effects are often most prominent during first 
administration of the drug 
• Side effects are fewer than chemotherapy 
• Rituxan used with chemotherapy may be more 
effective than chemotherapy alone 2,15,17,19 
 
Risks    
• Side effects often include: 
o Fever and chills (especially with first 
administration) 
o Nausea 
o Headache 
o Weakness 
• Must be used with caution in those with 
cardiovascular disease 
• Not clear whether biologic therapy lengthens 
survival 
• Biologic therapy not as well studied as 
chemotherapy 
• Patients with large amounts of cancerous tissue 
must be monitored carefully because cellular 
contents may be released when cancer cells are 
killed, which can be fatal 2,15,17,20 
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Stem Cell Transplantation 
 
In Stem Cell Transplantation, the patient is first given high dose 
chemotherapy to destroy the lymphoma cells. When this high dose 
chemotherapy is given, it can destroy much of the bone marrow 
tissue making it necessary to replace the tissue that has been 
destroyed. In a Stem Cell Transplant, bone marrow stem cells are 
infused into the blood stream following chemotherapy. These stem 
cells will make their way to the bone marrow, where they will grow 
and create new blood cells. 
 
Stem cells used for transplant must be obtained from a donor. There 
are two types of donors: 
! Autologous: The patient acts as his or her own donor. During 
a time of remission, the patient is given a drug that will 
increase the number of stem cells in the blood stream. The 
stem cells are collected through a machine and the rest of 
the blood is infused back into the patient. The stem cells are 
saved and infused into the patients blood stream after 
chemotherapy. 
! Allogeneic: Stem cells from a sibling or other donor who 
genetically meets criteria are used. The stem cells are 
collected from the donor in a similar procedure to the 
autologous transplant. These stem cells are infused into the 
patients blood stream following chemotherapy. 
 
During and following the transplant, patients are hospitalized for 
several weeks to several months. Since much of the bone marrow 
has been destroyed and thus the bone marrow is not producing new 
blood cells, patients often need blood cell replacements during this 
time. 
 
A common complication that can occur with an allogeneic donor is 
Graft Versus Host Disease. This occurs when the donors bone 
marrow cells recognize the patients original cells as foreign and 
begin to work against them. This disease can affect the skin, liver, 
gastrointestinal tract, eyes, and lung. It can last from several weeks 
to years, and can sometimes be fatal.15 
Stem Cell Transplantation 
Benefits  
• Offers a safer way to deliver higher doses of 
chemotherapy 
• Autologous transplants have no risk for Graft 
Versus Host Disease 
• There is potential for a cure with this treatment, or 
at least a lengthened amount of time before the 
disease recurs 2,15,17 
 
Risks    
• Since transplants begin with chemotherapy, side 
effects related to chemotherapy will often occur 
• Can take several months to years for the immune 
system to fully rebuild itself, so there will be an 
increased risk for infections during that time 
• Need for blood and platelet transfusions until the 
bone marrow starts producing cells 
• Long hospitalization following transplant and 
continual monitoring and possible re-
hospitalizations after transplant 
• Possible Graft Versus Host Disease in allogeneic 
transplants 
• May increase the risk of developing other cancers 
in the future 2,15,17 
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Watch and Wait 
 
In Watch and Wait, although active sites of disease are 
present, if there are no symptoms of lymphoma, 
treatment is withheld until deemed necessary. Treatment 
is often withheld until symptoms of the disease are 
present. (Possible symptoms are listed on page 5). 
 
During this period, the patient is closely followed by their 
oncologist with frequent radiological scans, medical tests, 
and examinations of lymph nodes. 
 
The reason that Watch and Wait can be used with 
Indolent Follicular Lymphoma, is that because the 
disease is slow-growing, so patients can often survive for 
very long periods of time without any treatment.15,17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Watch and Wait 
 
Benefits  
• Since no treatment is being given, there are no 
side effects of Watch and Wait 
• Although aggressive chemotherapy may lengthen 
periods in which patients are without symptoms, 
these treatments do not necessarily prolong 
survival. Watch and Wait allows the patient to 
avoid side effects and complications often 
associated with treatments without necessarily 
shortening survival time.2,15 
 
Risks    
• Anxiety related to not actively treating the 
lymphoma 
• Patient may have some symptoms of Follicular 
Lymphoma if they are present, or symptoms may 
occur 
• Frequent checkups with oncologist, which include 
radiological scans and other diagnostic tests 2,15 
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Clinical Trials 
 
Clinical trials are controlled research studies in which 
new drugs or new devices are tested in patients to 
determine their effectiveness. New combinations of 
currently used treatments may also be tested. 
 
All studies must be approved by an Institutional Review 
Board and the patients signature must be obtained 
before the patient can participate. The risks and benefits 
of participating in a study are explained to the patient 
beforehand. 
 
One thing to keep in mind is that because different 
treatments are often compared in these studies, patients 
may be randomly assigned to treatments.15 
 
Information about current clinical trials can be obtained 
from: 
$ Asking your oncologist about available options 
$ National Cancer Institute: 
www.cancer.gov/clinicaltrials or 1-800-4CANCER 
$ American Cancer Society: www.cancer.org or 1-
800-ACS-2345 
$ Lymphomation: www.lymphomation.org 
 
 
 
 
 
 
 
Clinical Trials 
 
Benefits  
• Might have access to highly effective treatments 
that are currently being studied 
• Will contribute to further understanding of 
treatment for lymphoma 
• May receive treatment without monetary cost2,15 
 
 
Risks    
• May not have choice about which treatments you 
receive 
• Treatment may not result in improved outcome 
• Anxiety related to being randomly assigned to 
treatment groups or not knowing what effect the 
treatment may have2,15 
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Questions to Ask Your Doctor 
 
Here is a list of questions that might be useful to discuss 
with your doctor: 
 
What side effects from these treatments are likely to 
affect me? 
 
Which treatments would you recommend? Why? 
 
How many treatments will I have to take? 
 
What is the survival rate with these treatments for 
patients with disease similar to mine? 
 
What is the average length of time for remission with 
these treatments for patients with disease similar to 
mine? 
 
What will these treatments do to my body? 
 
What can I do to help prevent or minimize side effects 
from these treatments? 
 
What are my options for emotional support during these 
treatments? 
 
 
 
 
 
 
Patient Decision Example: 
Catherines Situationa 
 
Below is an example of a patient going through steps to 
make a decision about treatment. 
 
 
What is the decision you need to make? 
Which treatment to choose for my follicular 
lymphoma 
 
Do you know what options you have? 
Yes 
 
Do you know the good and bad points about each 
option? 
Yes 
 
What are the factors most important to you in determining 
your decision? 
Avoiding spending too much time as a patient in the 
hospital 
Dont want to be nauseated 
Minimizing side effects from treatments 
Staying in remission for as long as possible and 
surviving as long as possible 
 
 
 
a Worksheet adapted from the Ottawa Personal Decision Guide21 
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Catherines Situationa 
1. Please list and review only the options you are considering. 
You do not have to fill in all of the spaces provided for 
options. 
2. List the pros and cons of each option for you. 
3. Show how important each pro or con is to you by placing 
one star (*) to five stars (*****) beside each item. 
 
 Pros Personal 
Importance 
to me (*) 
Cons Personal 
Importance 
to me (*) 
Option 1 
is: 
 
Chemo-
therapy 
-Probably 
wont have to 
stay in 
hospital 
-Have drugs 
for nausea 
***** 
 
 
***** 
 
*** 
-Might get 
nauseated 
-Dont know 
if it will 
increase my 
survival 
***** 
 
***** 
 
 
***** 
Option 2 
is: 
 
 
Biologic 
therapy 
 
 
-Probably 
wont have to 
stay in 
hospital 
-Have drugs 
for nausea 
-Side effects 
wont last 
long 
***** 
 
 
***** 
 
*** 
-Might get 
nauseous 
-Dont know 
if it will 
increase my 
survival 
***** 
 
***** 
Option 3 
is: 
A 
clinical 
trial 
-Will help the 
doctors learn 
about 
treatments  
** 
 
 
 
-Probably 
wont get to 
choose  
 
 
**** 
 
 
 
 
a Worksheet adapted from the Ottawa Personal Decision Guide21 
 
 
 
 
Catherines Situation 
 
 Pros Personal 
Importance 
to me (*) 
Cons Personal 
Importance 
to me (*) 
Option 4 
is: 
 
 
Watch and 
Wait 
 
 
 
-Probably 
wont have 
to stay in 
hospital 
-Wont have 
side effects 
-May not 
decrease 
my 
survival 
***** 
 
 
 
***** 
 
***** 
-Will worry 
about how 
long I will 
be in 
remission 
-Will get 
frequent 
medical 
tests 
**** 
 
 
 
** 
Option 5 
is: 
 
 
 
 
 
 
 
    
Option 6 
is: 
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For Additional Information 
 
Websites 
$ National Cancer Institute: www.cancer.gov 
$ American Cancer Society: www.cancer.org 
$ Lymphomation: www.lymphomation.org 
$ Leukemia and Lymphoma Society: www.lls.org 
 
Books 
$ Holman, P., Garrett, J., & Jansen, W. (2004). 100 
Questions and Answers about Lymphoma. 
Sudbury, MA: Jones and Bartlett Publishers. 
$ Johnston, L. (1999). Non-Hodgkins Lymphomas: 
Making sense of diagnosis, treatment, and 
options. Sebastopol, CA: OReilly. 
 
Telephone Numbers 
$ National Cancer Institute: 1-800-4CANCER 
$ American Cancer Society: 1-800-ACS-2345 
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Please complete the two pages of this My Situation form as if 
you were trying to make a decision about treatment as the patient 
in Maxs Situation. Feel free to review the information in the 
decision aid that you just read. 
 
My Situationa 
 
What is the decision you need to make? 
 
 
 
 
 
 
Do you feel you know what options you have? 
 
 
 
 
 
 
Do you feel you know the good and bad points about each option? 
 
 
 
 
 
 
 
What are the factors most important to you in determining your decision? 
 
 
 
 
 
a Worksheet adapted from the Ottawa Personal Decision Guide21 
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My Situationa 
1    Please list and review the options you are considering. You do not need to list all possible options. List only those you are 
considering. 
2    List the pros and cons of each option for you. 
3     Show how important each pro or con is to you by placing one star (*) to five stars (*****) beside each item. 
 
 Pros Personal 
Importance 
to me (*) 
Cons Personal 
Importance to 
me (*) 
Option 1 is: 
 
 
 
 
 
 
    
Option 2 is: 
 
 
 
 
 
 
    
Option 3 is: 
 
 
 
 
 
 
    
Option 4 is: 
 
 
 
 
 
 
    
Option 5 is: 
 
 
 
 
 
    
Option 6 is: 
 
 
 
 
 
    
a Worksheet adapted from the Ottawa Personal Decision Guide21 
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Appendix B 
Semi-Structured Interview 
What information about the disease is important in evaluating treatment options? 
 
 
 What information about treatment is important in evaluating treatment options? 
 
 
What questions should a patient ask a physician about treatment options? 
 
 
What format would you prefer in a decision aid (e.g., picture illustrations, amount of information 
per page, overall length of aid, bullet points vs. paragraphs)? 
 
 
What information do you think would be important to include in a treatment decision scenario 
for a patient who is attempting to choose among treatment options for recurrent follicular 
lymphoma? 
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Appendix C 
 
Decision Aid Evaluation Questionnaire 
 
Please answer each question after reading the decision aid. You will be asked 
questions about each section of the decision aid. 
 
The Lymphatic System: Circle the number that best represents how much you agree 
with each statement (1=disagree, 2=somewhat disagree, 3= somewhat agree, 
4=agree). 
                                                                                    Somewhat       Somewhat  
                                                                            Disagree       Disagree           Agree            Agree 
 
The information about the lymphatic           1                2                 3                4  
system was useful                                         
 
The information about the lymphatic           1                2                 3                4 
system was relevant to me 
 
The information about the lymphatic           1                2                 3                4 
system was clear 
 
The information about the lymphatic           1                2                 3                4 
system was understandable 
 
The information about the lymphatic           1                2                 3                4 
system was applicable to my 
situation 
 
 
What information would you like to see added to the information about the lymphatic 
system? 
 
 
 
 
What information would you like to see deleted from the information about the lymphatic 
system? 
 
 
 
 
What other modifications would like to see made to the information about the lymphatic 
system? 
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The Lymphomas and Follicular Lymphoma: Circle the number that best represents how 
much you agree with each statement (1=disagree, 2=somewhat disagree, 3= somewhat 
agree, 4=agree). 
                                                                                    Somewhat       Somewhat  
                                                                            Disagree       Disagree           Agree            Agree 
 
The information about the lymphomas         1                2                 3                4  
and follicular lymphoma was useful                                         
 
The information about the lymphomas         1                2                 3                4  
and follicular lymphoma was relevant  
to me 
 
The information about the lymphomas         1                2                 3                4  
and follicular lymphoma was clear 
 
The information about the lymphomas         1                2                 3                4  
and follicular lymphoma was  
understandable 
 
The information about the lymphomas         1                2                 3                4  
and follicular lymphoma was applicable 
 to my situation 
 
 
What information would you like to see added to the information about the lymphomas 
and follicular lymphoma? 
 
 
 
 
What information would you like to see deleted from the information about the 
lymphomas and follicular lymphoma? 
 
 
 
 
 
What other modifications would like to see made to the information about the 
lymphomas and follicular lymphoma? 
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Chemotherapy: Circle the number that best represents how much you agree with each 
statement (1=disagree, 2=somewhat disagree, 3= somewhat agree, 4=agree). 
                                                                                    Somewhat       Somewhat  
                                                                            Disagree       Disagree           Agree            Agree 
 
The information about chemotherapy          1                2                 3                4  
was useful                                         
 
The information about chemotherapy          1                2                 3                4  
was relevant to me 
 
The information about chemotherapy          1                2                 3                4  
was clear 
 
The information about chemotherapy         1                2                 3                4  
was understandable 
 
The information about chemotherapy         1                2                 3                4  
was applicable to my situation 
 
 
What information would you like to see added to the information about chemotherapy? 
 
 
 
 
What information would you like to see deleted from the information about 
chemotherapy? 
 
 
 
 
 
What other modifications would like to see made to the information about 
chemotherapy? 
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Radiation: Circle the number that best represents how much you agree with each 
statement (1=disagree, 2=somewhat disagree, 3= somewhat agree, 4=agree). 
                                                                                    Somewhat       Somewhat  
                                                                            Disagree       Disagree           Agree            Agree 
 
The information about radiation                   1                2                 3                4  
was useful                                         
 
The information about radiation                   1                2                 3                4  
was relevant to me 
 
The information about radiation                   1                2                 3                4  
was clear 
 
The information about radiation                   1                2                 3                4  
was understandable 
 
The information about radiation                   1                2                 3                4  
was applicable to my situation 
 
 
What information would you like to see added to the information about radiation? 
 
 
 
 
What information would you like to see deleted from the information about radiation? 
 
 
 
 
 
What other modifications would like to see made to the information about radiation? 
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Biologic Therapy: Circle the number that best represents how much you agree with 
each statement (1=disagree, 2=somewhat disagree, 3= somewhat agree, 4=agree). 
                                                                                    Somewhat       Somewhat  
                                                                            Disagree       Disagree           Agree            Agree 
 
The information about biologic                    1                2                 3                4  
therapy was useful                                         
 
The information about biologic                    1                2                 3                4  
therapy was relevant to me 
 
The information about biologic                    1                2                 3                4  
therapy was clear 
 
The information about biologic                    1                2                 3                4  
therapy was understandable 
 
The information about biologic                    1                2                 3                4  
therapy was applicable to my situation 
 
 
What information would you like to see added to the information about biologic therapy? 
 
 
 
 
What information would you like to see deleted from the information about biologic 
therapy? 
 
 
 
 
 
What other modifications would like to see made to the information about biologic 
therapy? 
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Stem Cell Transplantation: Circle the number that best represents how much you agree 
with each statement (1=disagree, 2=somewhat disagree, 3= somewhat agree, 
4=agree). 
                                                                                    Somewhat       Somewhat  
                                                                            Disagree       Disagree           Agree            Agree 
 
The information about stem cell                  1                2                 3                4  
transplantation was useful                                         
 
The information about stem cell                  1                2                 3                4  
transplantation was relevant to me 
 
The information about stem cell                  1                2                 3                4  
transplantation was clear 
 
The information about stem cell                  1                2                 3                4  
transplantation was understandable 
 
The information about stem cell                  1                2                 3                4  
transplantation was applicable to  
my situation 
 
 
What information would you like to see added to the information about stem cell 
transplantation? 
 
 
 
 
What information would you like to see deleted from the information about stem cell 
transplantation? 
 
 
 
 
 
What other modifications would like to see made to the information about stem cell 
transplantation? 
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Watch and Wait: Circle the number that best represents how much you agree with each 
statement (1=disagree, 2=somewhat disagree, 3= somewhat agree, 4=agree). 
                                                                                    Somewhat       Somewhat  
                                                                            Disagree       Disagree           Agree            Agree 
 
The information about watch and                1                2                 3                4  
wait was useful                                         
 
The information about watch and                1                2                 3                4  
wait was relevant to me 
 
The information about watch and                1                2                 3                4  
wait was clear 
 
The information about watch and                1                2                 3                4  
wait was understandable 
 
The information about watch and                1                2                 3                4  
wait was applicable to my situation 
 
 
What information would you like to see added to the information about watch and wait? 
 
 
 
 
What information would you like to see deleted from the information about watch and 
wait? 
 
 
 
 
 
What other modifications would like to see made to the information about watch and 
wait? 
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Clinical Trials: Circle the number that best represents how much you agree with each 
statement (1=disagree, 2=somewhat disagree, 3= somewhat agree, 4=agree). 
                                                                                    Somewhat       Somewhat  
                                                                            Disagree       Disagree           Agree            Agree 
 
The information about clinical trials             1                2                 3                4  
was useful                                         
 
The information about clinical trials             1                2                 3                4  
was relevant to me 
 
The information about clinical trials             1                2                 3                4  
was clear 
 
The information about clinical trials             1                2                 3                4  
was understandable 
 
The information about clinical trials             1                2                 3                4  
was applicable to my situation 
 
 
What information would you like to see added to the information about clinical trials? 
 
 
 
 
What information would you like to see deleted from the information about clinical trials? 
 
 
 
 
 
What other modifications would like to see made to the information about clinical trials? 
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Appendix D 
 
Patient Demographic Questionnaire 
 
Please answer the following questions. 
 
 
Date of Birth___________________ 
 
 
Gender: (circle)     Male       Female 
 
 
Ethnicity: (circle)     Caucasian/White        
            African American/Black          
            Hispanic/Latino 
            Other__________________ 
 
 
Education: (circle one)     12th grade or below 
          High School Graduate 
          Some college 
          College Graduate 
          Graduate School 
  
130
Appendix E 
 
Patient Scenario 
 
Maxs Situation 
 
Please read the following patient situation: 
 
Max is a 48-year-old Caucasian male from Morgantown, West Virginia. He has 
been married to Susan for 23 years. They have two children, Sam (age 19) and Steve 
(age 21). Both of his children are currently students at West Virginia University. Max has 
been employed as a construction worker for the last 18 years.  
Max was diagnosed with Stage III indolent follicular non-Hodgkins lymphoma 
nine months ago. Since his diagnosis, he has undergone treatment with six cycles of 
chemotherapy. Now that the chemotherapy has finished, his oncologist has conducted 
some tests and has discovered that he still has some slow-growing active disease in 
several lymph nodes in his abdomen. Max must decide which type of treatment he 
should pursue. His oncologist has told him that his options are very open at this point. 
He may choose to undergo more chemotherapy or to begin one of several other 
therapies (e.g., radiation, biologic therapy, or a stem cell transplant). He also may 
explore available clinical trials. Since the only symptom he is currently experiencing is 
occasional night sweats, his oncologist has also given him the option to watch and wait 
before beginning active treatment. 
Before receiving the diagnosis of follicular lymphoma, Max did not have a history 
of major medical problems. His only history of illness included developing a cold about 
once per year. 
Max would be able to receive any of these treatments at his local hospital. His 
insurance has agreed to cover any of these options, and his current boss is willing to 
give him as much unpaid time off as he needs to recover from treatment. 
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Appendix F 
 
Patient Scenario Evaluation Questionnaire 
 
Please answer these questions after reading Maxs Situation. 
 
                                                            Not very                                     Very 
                                                            Believable                              Believable 
 
How believable is Maxs situation?           1              2              3              4 
          (circle one number of the scale) 
 
 
 
Please answer the following questions: 
 
What information do you think should be added to the information presented in Maxs 
situation that might influence his decision about treatment? 
 
 
 
 
 
 
 
What information do you think should be deleted from the information presented in 
Maxs situation that would be irrelevant or unimportant in his decision about treatment? 
 
 
 
 
 
What other modifications do you think should be made to Maxs situation that might 
influence his decision about treatment? 
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Appendix G 
 
 
Comparison Decision Aid
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A Decision Aid for Patients 
with Indolent 
Follicular non-Hodgkins 
Lymphoma 
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The Lymphatic System 
 
 
The lymphatic system consists of several body parts 
including: 
• spleen 
• thymus 
• tonsils 
• bone marrow 
• lymph nodes (These are the size of a bean and 
are distributed throughout the body. Clusters of 
lymph nodes are found in the armpits, abdomen, 
groin, pelvis, collarbone area, and neck.)3,4 
 
 
 
The Lymphatic System 
 
What does the lymphatic system do?     
 
 
! The lymphatic system includes vessels that 
transport fluids throughout the body. A fluid called 
lymph is circulated throughout the lymphatic 
system. This fluid contains white blood cells, which 
are also called lymphocytes. These lymphocytes 
are created in the bone marrow and mature in the 
thymus. They are important in the bodys ability to 
fight infection. 
 
! The spleen and the lymph nodes are filters of the 
lymph fluid. 
 
! When your body is fighting an infection such as 
from bacteria or viruses, the lymph nodes will 
swell with lymphocytes that will target and destroy 
these unwanted organisms in the body.3,4,5 
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The Lymphomas 
 
Almost all cells in the human body have the ability to 
divide to produce new cells that can replace the cells that 
die. However, cancer results from a defect within a cell 
that causes the cell to continue to divide faster than the 
rate of cell death. These cancerous cells inhibit the 
growth and survival of normal cells.6  
 
The lymphomas are cancers of the lymphocytes. 
Lymphomas are divided into Hodgkins Lymphoma and 
non-Hodgkins Lymphoma. Non-Hodgkins Lymphoma is 
the most common type of lymphoma. 
 
Non-Hodgkins Lymphoma can be categorized in several 
ways:2,7,8 
By grade: 
  Indolent or Low Grade (slow growing) 
  Intermediate Grade (moderate growth rate) 
  Aggressive or High Grade (fast growing) 
 By stage: 
  Stage I: lymphoma detected in one lymph 
node 
Stage II: lymphoma detected in two or more 
lymph nodes near each other 
Stage III: lymphoma detected in several 
lymph nodes far apart 
Stage IV: widespread involvement of lymph 
nodes as well as organs such as liver, 
lungs, or bone 
 
 
What is Follicular non-Hodgkins Lymphoma? 
 
Follicular Lymphoma is an Indolent (Low Grade) lymphoma. It 
is the second most common type of non- Hodgkins 
lymphoma.9 
 
Follicular Lymphoma is a slow-growing cancer of specific kinds 
of lymphocytes called B-cells.10 These cancer cells are 
grouped in clusters, which are called follicles, in the lymph 
nodes. 
 
For patients diagnosed with Follicular Lymphoma, especially 
those in which the disease is more widespread than Stage I, 
the disease may be considered incurable. This means that 
even after treatment, the disease can be expected to remain 
dormant in the body and may recur. More aggressive 
treatment may lengthen the amount of time between 
recurrences.9,11 
 
With new and better treatment options available, the length of 
survival for patients with follicular lymphoma has been 
increasing over the years.12 
 
Symptoms of follicular lymphoma can be difficult to identify 
and thus, most patients present with advanced-stage 
disease.10 
 
Possible symptoms include: 
• Fever 
• Fatigue 
• Itchy skin 
• Drenching night sweats 
• Unexplained weight loss 
• Pain in chest, bones, or abdomen 
• Painless swelling of lymph nodes 
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Treatments for Follicular non-Hodgkins Lymphoma 
 
Treatments available to each patient will depend upon 
several factors including stage of disease, whether 
organs outside of lymph nodes are affected, the 
lymphomas cell type, patient age, and current 
symptoms.2 
 
Current treatment options for follicular lymphoma 
include:2,13 
 
Chemotherapy 
 Radiation 
 Biologic Therapy 
 Stem Cell Transplantation 
 Watch and Wait 
 Clinical Trial 
As of today, there is no consensus among oncologists 
about which treatment option is the best.14 
 
 
 
 
 
 
 
 
 
 
Chemotherapy 
 
Chemotherapy is commonly used when a patient is first 
diagnosed, but is also used when the disease recurs.10 
 
Chemotherapy is a drug that is either injected into the 
veins or swallowed orally. Once the drug enters the body, 
it is carried by the blood stream to areas throughout the 
body. These drugs are designed to either kill the cancer 
cells or to stop their ability to multiply.7 
 
Chemotherapy drugs can be used alone, in combination 
with other chemotherapy drugs, or in combination with 
some of the treatments mentioned in the next few 
sections (e.g., radiation, biologic therapy, or stem cell 
transplantation).2,15 Chemotherapy may also be 
combined with steroids. Most chemotherapy treatment 
will require more than one session of treatment. The 
number of sessions will depend on your specific case. 
Each type of chemotherapy can have its own different 
possible risks and benefits. 
 
Examples of common chemotherapy regimens: 
# CHOP: Cyclophosphamide, Doxorubicin, 
Vincristine, Prednisone 
# CVP: Cyclophosphamide, Vincristine, Prednisone 
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Radiation 
 
Radiation is a treatment that kills lymphoma cells in a 
specific area using high-energy rays.2 The rays work to 
damage the DNA in the lymphoma cells, which can 
cause death of the cancerous cells.15  
 
Before administering radiation, scans will be used to map 
out a specific area on the body for administration of the 
radiation to limit the number of healthy cells that are 
damaged. Treatment usually takes several sessions. 
These sessions typically last about 15 minutes, with 
repeated sessions for several weeks.15 
 
Radiation can be used when the patient has a large area 
of lymphoma cells within a small area of the body, or 
when enlarged lymph nodes are interfering with other 
organs.2 Radiation can be used alone, or it is often used 
in combination with chemotherapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biologic Therapy 
 
In the human body, antibodies are produced by the immune 
system to help the body know which substances are foreign 
and should be destroyed. Biologic Therapy involves 
treatments that use antibodies to fight the lymphoma.18 
 
Monoclonal Antibody Therapy is a type of biologic therapy in 
which an antibody is injected into the blood. When a 
Monoclonal Antibody is circulated throughout the system, it 
seeks out and destroys lymphoma cells. Monoclonal Antibody 
Therapy is often used in conjunction with chemotherapy.2,17 
 
Radioimmunotherapy is a form of biologic therapy that uses a 
radioactive substance, which is carried to the lymphoma cells 
by monoclonal antibodies. This treatment targets the 
lymphoma cells directly and leaves normal cells intact.2 
 
Examples of Biologic Therapy:17 
# Rituxan: This monoclonal antibody treatment is usually 
injected into the veins every week for about four 
weeks. Each treatment can take anywhere from 4 to 8 
hours, with the first treatments typically taking the 
longest. 
# Zevalin or Bexxar: These radioimmunotherapies are 
actually a form of radiation and are given along with 
Rituxan. It takes seven to nine days to administer. Over 
the course of therapy, body scans are conducted to 
determine how the radiation has distributed throughout 
the body. Radiation is delivered directly to the 
lymphoma cells, which helps to protect normal cells. 
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Stem Cell Transplantation 
 
In Stem Cell Transplantation, the patient is first given high dose 
chemotherapy to destroy the lymphoma cells. When this high dose 
chemotherapy is given, it can destroy much of the bone marrow 
tissue making it necessary to replace the tissue that has been 
destroyed. In a Stem Cell Transplant, bone marrow stem cells are 
infused into the blood stream following chemotherapy. These stem 
cells will make their way to the bone marrow, where they will grow 
and create new blood cells. 
 
Stem cells used for transplant must be obtained from a donor. There 
are two types of donors: 
! Autologous: The patient acts as his or her own donor. During 
a time of remission, the patient is given a drug that will 
increase the number of stem cells in the blood stream. The 
stem cells are collected through a machine and the rest of 
the blood is infused back into the patient. The stem cells are 
saved and infused into the patients blood stream after 
chemotherapy. 
! Allogeneic: Stem cells from a sibling or other donor who 
genetically meets criteria are used. The stem cells are 
collected from the donor in a similar procedure to the 
autologous transplant. These stem cells are infused into the 
patients blood stream following chemotherapy. 
 
During and following the transplant, patients are hospitalized for 
several weeks to several months. Since much of the bone marrow 
has been destroyed and thus the bone marrow is not producing new 
blood cells, patients often need blood cell replacements during this 
time. 
 
A common complication that can occur with an allogeneic donor is 
Graft Versus Host Disease. This occurs when the donors bone 
marrow cells recognize the patients original cells as foreign and 
begin to work against them. This disease can affect the skin, liver, 
gastrointestinal tract, eyes, and lung. It can last from several weeks 
to years, and can sometimes be fatal.15 
Watch and Wait 
 
In Watch and Wait, although active sites of disease are 
present, if there are no symptoms of lymphoma, 
treatment is withheld until deemed necessary. Treatment 
is often withheld until symptoms of the disease are 
present. (Possible symptoms are listed on page 4). 
 
During this period, the patient is closely followed by their 
oncologist with frequent radiological scans, medical tests, 
and examinations of lymph nodes. 
 
The reason that Watch and Wait can be used with 
Indolent Follicular Lymphoma, is that because the 
disease is slow-growing, so patients can often survive for 
very long periods of time without any treatment.15,17 
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Clinical Trials 
 
Clinical trials are controlled research studies in which 
new drugs or new devices are tested in patients to 
determine their effectiveness. New combinations of 
currently used treatments may also be tested. 
 
All studies must be approved by an Institutional Review 
Board and the patients signature must be obtained 
before the patient can participate. The risks and benefits 
of participating in a study are explained to the patient 
beforehand. 
 
One thing to keep in mind is that because different 
treatments are often compared in these studies, patients 
may be randomly assigned to treatments.15 
 
Information about current clinical trials can be obtained 
from: 
$ Asking your oncologist about available options 
$ National Cancer Institute: 
www.cancer.gov/clinicaltrials or 1-800-4CANCER 
$ American Cancer Society: www.cancer.org or 1-
800-ACS-2345 
$ Lymphomation: www.lymphomation.org 
 
 
 
 
 
 
 
For Additional Information 
 
Websites 
$ National Cancer Institute: www.cancer.gov 
$ American Cancer Society: www.cancer.org 
$ Lymphomation: www.lymphomation.org 
$ Leukemia and Lymphoma Society: www.lls.org 
 
Books 
$ Holman, P., Garrett, J., & Jansen, W. (2004). 100 
Questions and Answers about Lymphoma. 
Sudbury, MA: Jones and Bartlett Publishers. 
$ Johnston, L. (1999). Non-Hodgkins Lymphomas: 
Making sense of diagnosis, treatment, and 
options. Sebastopol, CA: OReilly. 
 
Telephone Numbers 
$ National Cancer Institute: 1-800-4CANCER 
$ American Cancer Society: 1-800-ACS-2345 
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Appendix H 
 
Ratings and Rankings of Treatment Preference 
 
If you were in Maxs situation, please circle the number that most corresponds with how 
much you would prefer to receive each treatment (4=would definitely prefer to 1=would 
definitely not prefer) 
                                                 
                                     Would                                                  Would 
                                       Not                                                   Definitely 
                                      Prefer                                                  Prefer 
 
Chemotherapy                  1                 2                   3                  4 
 
Radiation                           1                 2                   3                  4 
 
Biologic Therapy               1                 2                   3                  4 
 
Stem Cell Transplant        1                 2                   3                  4 
 
Watch and Wait                1                 2                   3                  4 
  
Clinical Trial                      1                 2                   3                  4 
 
 
 
Please rank order the treatments from 1 to 6 in order of what you feel is the best 
treatment option, with 1=the best treatment option and 6=the worst treatment option. 
 
                                ____Chemotherapy 
 
                                ____Radiation 
 
                                ____Biologic Therapy 
 
                                ____Stem Cell Transplant 
 
                                ____Watch and Wait 
 
                                ____Clinical Trial 
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Appendix I 
 
Knowledge Test 
 
Please read each question and circle the best possible answer.  
 
1. Stage II lymphoma is defined as: 
a. Lymphoma detected in blood vessels 
b. Lymphoma detected in several lymph nodes far apart 
c. Lymphoma detected in two or more lymph nodes close together 
d. Lymphoma detected in one lymph node 
 
2. Which of the following lists include only organs that are part of the lymphatic 
system? 
a. Spleen, thymus, heart, bone marrow 
b. Spleen, pancreas, thymus, bone marrow 
c. Spleen, thymus, bone marrow, tonsils 
d. Thymus, pancreas, lymph nodes, bone marrow 
 
3. Which is the most common type of lymphoma? 
a. Hodgkins lymphoma 
b. Non-Hodgkins lymphoma 
c. Burkitts lymphoma 
d. Follicular lymphoma 
 
4. Which grade of cancer is follicular lymphoma? 
a. Irregular 
b. Aggressive or High Grade 
c. Intermediate 
d. Indolent or Low Grade 
 
5. All of the following are common possible symptoms of follicular lymphoma 
EXCEPT: 
a. Blurred vision 
b. Night sweats 
c. Itchy skin 
d. Fatigue 
 
6. All of the following are possible treatments for follicular lymphoma EXCEPT: 
a. Radiation 
b. Laser therapy 
c. Biologic therapy 
d. Stem cell transplants 
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7. Advanced stage lymphoma is likely to occur: 
a. Only in the neck and abdomen 
b. In organs 
c. Only in the lymph nodes 
d.  In hair and nail tissue 
 
8. Which of the following is a risk of using chemotherapy? 
a. Most side effects continue after treatment is finished 
b. The wrong chemotherapy may increase the severity of the cancer 
c. Chemotherapy is typically not well-tolerated in patients 
d. Chemotherapy may damage other organs 
 
9. Chemotherapy is used for follicular lymphoma: 
a. When the disease is first diagnosed 
b. When the disease has recurred 
c. When the disease is first diagnosed or has recurred 
d. After all other forms of treatment have been exhausted 
 
10. Radiation for follicular lymphoma: 
a. Uses high-energy rays to kill cancer cells 
b. Is introduced with a radioactive pill that is swallowed 
c. Both a and b 
d. None of the above 
 
11. All of the following are relative benefits of using radiation to treat lymphoma 
EXCEPT: 
a. Most side effects end soon after treatment is finished 
b. Can be used for disease that has spread throughout the body 
c. Can reduce the number of chemotherapy cycles needed 
d. Treatments are short in duration 
 
12. Radioimmunotherapy is a form of: 
a. Bone Marrow Transplantation 
b. Chemotherapy 
c. Antibiotic therapy 
d. Biologic therapy 
 
13. Monoclonal Antibody Therapy: 
a. Seeks out cancer cells 
b. Cannot be used with chemotherapy 
c. Is a form of chemotherapy 
d. Is a form of antibiotic therapy 
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14. In which type of transplant are stem cells donated from the patients themselves: 
a. Allogeneic 
b. Autologous 
c. Autonomic 
d. Autoimmune 
 
15. What type of cells can be transplanted in a stem cell transplant for follicular 
lymphoma patients? 
a. Bone marrow 
b. Liver 
c. Spinal 
d. Lymph 
 
16. The side effect called graft versus host disease: 
a. Does not occur in an autologous transplant 
b. Does not occur in an allogeneic transplant 
c. Has no symptoms 
d. Results from too much chemotherapy 
 
17.  A watch and wait approach is used primarily when: 
a. There is no disease present in the patient 
b. All treatment options have already been pursued 
c. The patient is waiting for a stem cell transplant 
d. The patient does not have active symptoms 
 
18. Which of the following is NOT a risk of watch and wait: 
a. Requires frequent physician check-ups 
b. Patient may experience anxiety 
c. May shorten length of survival 
d. Patient may have some symptoms 
 
19. A clinical trial is: 
a. A research study testing new treatment options 
b. A research study testing the effects of cancer on patients 
c. A research study in which patients choose which treatment options to 
pursue 
d. A research study that tests effects of hospital stays on cancer patients 
 
20. Clinical trials involve: 
a. Not informing patient of the risks of the study 
b. Approval from an Institutional Review Board 
c. Approval from a Congressional Review Board 
d. Both a and b 
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Appendix J 
 
Sociodemographic Questionnaire 
 
Please answer the following questions. 
 
 
Date of Birth___________________ 
 
 
Gender: (circle)     Male       Female 
 
 
Ethnicity: (circle)     Caucasian/White        
            African American/Black          
            Hispanic/Latino 
            Other__________________ 
 
 
Education: (circle one)     12th grade or below 
          High School Graduate 
          Some college 
          College Graduate 
          Graduate School 
 
Have you ever known anyone with cancer? (circle one)          yes        no 
 
 
Have you helped someone make a decision about treatment for cancer? (circle one)      yes       no 
 
 
Have you ever known anyone with lymphoma? (circle one)      yes      no 
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Appendix K 
 
Opinion of the Decision Aid 
 
Please answer the following questions. 
 
 
What aspects of the Decision Aid were the most helpful in making your decision about treatment? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
What aspects of the Decision Aid were the least helpful in making your decision about treatment? 
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Appendix L 
 
Patient Responses to Semi-Structured Interview Questions 
 
What information about the disease is important in evaluating treatment options? 
Patient 1: broad information in an understandable format 
Patient 2: early symptoms, can have for a long time before you know it 
Patient 3: difference between Hodgkins and non-Hodgkins, symptoms and signs 
Patient 4: explain the disease and that the disease is long-term 
Patient 5: chance of being in remission 
Patient 6: how fast the disease needs to be treated 
Patient 7: what type it is, how fast does it grow 
Patient 8: what causes lymph nodes to become aggressive, list symptoms 
Patient 9: likelihood of spreading to other organs, causes 
 
What information about treatment is important in evaluating treatment options? 
Patient 1: side effects 
Patient 2: side effects, instructions for treatments 
Patient 3: how long the procedures take 
Patient 4: explain all treatments, side effects 
Patient 5: that its not as bad as everyone thinks 
Patient 6: talk about good stuff as well as bad 
Patient 7: length of treatment, that you wont always be sick, what the drug does in lay 
terms 
Patient 8: explain them in lay language, emphasize that not everyone gets sick 
Patient 9: explain options available 
 
What questions should patient ask a physician about treatment options? 
Patient 1: What treatments can I have?, Are there options besides standard treatments? 
Patient 2: Will I have pain?, Which treatment would you choose, doctor? 
Patient 3: How far along is my cancer?, Will I get side effects from treatments?, What is 
my chance of it coming back?, How long will I have to have treatment? 
Patient 4: What are the side effects? What side effects are likely to affect me? 
Patient 5: How long will the treatment last? 
Patient 6: What are the side effects? Will this hurt? What will this do to my body?  
Patient 7: Am I going to live? When can we start? Where can I get emotional support? 
What should I expect? 
Patient 8: How much risk to other vital organs?, What is normal time span for being in 
remission? 
Patient 9: What causes lymphoma?, What is the chance of it spreading? 
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What format would you prefer in the decision aid (e.g., picture illustrations, amount of 
information per page, overall length of aid, bullet points vs. paragraphs). 
Patient 1: would like pictures and examples, 5-10 pages, bullets and paragraphs combined 
Patient 2: pictures would be nice, 4-5 pages, paragraphs preferable, would like patient 
examples 
Patient 3: not sure about pictures, 15-20 pages, both paragraphs and lists, patient 
examples good 
Patient 4: no pictures, no more than 10 pages, not too detailed, prefer listed information, 
examples could be helpful 
Patient 5: lists of information, pictures are useful, examples could be useful 
Patient 6: would like pictures, 15-18 pages, examples would be useful but make sure they 
know the decision is their own, would like paragraphs 
Patient 7: visuals like a smiley face and tearful face, both paragraphs and lists, more than 
4 pages, examples would be a good idea 
Patient 8: picture of lymph system, at least 20 pages, lists and paragraphs, examples 
would be helpful 
Patient 9: pictures would be good, 4 to 5 pages, would prefer lists of information, lay 
language, patient example would be good 
 
What information do you think would be important to include in a treatment decision scenario 
for a patient who is attempting to choose among treatment options for recurrent follicular 
lymphoma? 
Patient 1: family information  
Patient 2: which treatment does the doctor recommend 
Patient 3: which treatment options, if they have medical leave of absence, do they have 
family support 
Patient 4: which treatments considering, distance from hospital 
Patient 5: describe the patients disease 
Patient 6: dont know 
Patient 7: family information, history with cancer, options available to them 
Patient 8: how early the disease was detected 
Patient 9: when it was diagnosed 
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Appendix M 
 
Patient Responses to Patient Scenario Evaluation 
 
What information do you think should be added to the information presented in Maxs situation 
that might influence his decision about treatment? 
Patient 1: more detail about each treatment option and side effects 
Patient 2: what information is available about each treatment option 
Patient 3: no comment 
Patient 4: what symptoms, side effects of each treatment 
Patient 5: treatments should start ASAP 
 
What information do you think should be deleted from the information presented in Maxs 
situation that would be irrelevant or unimportant in his decision about treatment?  
Patient 1: boss giving him time off unpaid 
Patient 2: delete the treatment options that are not as effective 
Patient 3: no comment 
Patient 4: all fine 
Patient 5: remove option of watch and wait 
 
What other modifications do you think should be made to Maxs situation that might influence 
his decision about treatment?  
Patient 1: more information about each treatment option 
Patient 2: more information regarding available clinical trials 
Patient 3: no comment 
Patient 4: all treatment options explained, make sure insurance will cover 
Patient 5: explain the cycle of growth of the cancer 
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Appendix N 
 
Patient Written Responses to Decision Aid Evaluation Questionnaire 
 
Lymphatic System 
Patient 1: no response 
Patient 2: no response 
Patient 3: no response 
Patient 4: would like lymphoma drawing in more detail and larger 
Patient 5: say you need to follow instructions in order to recover, make sure aware of side effects 
Patient 6: diagram is small, can you enlarge it? 
 
The Lymphomas and Follicular Lymphoma 
Patient 1: no response 
Patient 2: no response 
Patient 3: no response 
Patient 4: no response 
Patient 5: I understand the information, no other suggestions 
Patient 6: consider treatable but not curable rather than incurable 
 
Chemotherapy 
Patient 1: no response 
Patient 2: no response 
Patient 3: no response 
Patient 4: no response 
Patient 5: this was all I learned when I had chemo 
Patient 6: wide variety available and tested 
 
Radiation 
Patient 1: no response 
Patient 2: no response 
Patient 3: no response 
Patient 4: no response 
Patient 5: make sure patient understands what needs to be done before starting treatment 
Patient 6: no response 
 
Biologic Therapy 
Patient 1: no response 
Patient 2: no response 
Patient 3: no response 
Patient 4: no response 
Patient 5: Would the meds for nausea help with this treatment?, no other suggestions 
Patient 6: no response 
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Stem Cell Tranplantation 
Patient 1: no response 
Patient 2 :no response 
Patient 3: no response 
Patient 4: no response 
Patient 5: the time it takes to bring platelets back up to normal is a slow process 
Patient 6: SCT now done with or without complete ablation of bone marrow 
 
Watch and Wait 
Patient 1: no response 
Patient 2: no response 
Patient 3: no response 
Patient 4: no response 
Patient 5: make sure patients know what to look for as far as symptoms 
Patient 6: under risks-patient can become reluctant to begin treatment when necessary 
 
Clinical Trials 
Patient 1: no response 
Patient 2: no response 
Patient 3: no response 
Patient 4: no response 
Patient 5: no response 
Patient 6: trials in various stages or phases of testing 
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Appendix O 
Table 17 
Pearson Correlation Coefficients for Change in Satisfaction with Decision, Change in Decisional Conflict, and  Predictor 
Variables 
__________________________________________________________________________________________________________________________ 
                                 Satisfaction       Res.      Dec.        Res.       Age        Need        M/B      STAI     CES-D     Gender       Educ.    
                                                     Satis.     Conf.     Conf.                    for Cog. 
__________________________________________________________________________________________________________________________ 
 
Satisfaction               1.00         .481**    -.569**   -.256    -.473**      .017        .127       .094       -.181       -.089            -.031 
 
Satis. Residualized    .481**      1,00       -.143     -.494**  -.103          .339*      .074       .082       .153         .126            .133 
 
Decisional Conflict   -.569**     -.143       1.00      .582**   .672**      -.058      -.412*      -.278      .017        .091           -.005 
 
Conflict Residualized -.256       -.494**   .582**   1.00       .502**     -.189      -.290       -.115       -.127       -.105          -.151 
 
Age                           -.473**     -.103       .672**    .502**  1.00          .053       -.415*      -.217      .016        .137            .029 
                                                  
Need for                   .017           .339*      -.058      -.189       .053         1.00       -.045        -.067       .255        .488**       .046 
Cognition                         
 
Mon/Blunt               .127           .074        -.412*     -.290     -.415*      -.045       1.00         .161       .136        -.074           .002                  
 
STAI                         .094         .082          -.278      -.115      -.217        -.067      .161         1.00       .437**    -.249          -.207 
 
CES-D                      -.181        .153          .017        -.127      .016         .255       .136          .437**    1.00        .160          .090 
 
Gender                     -.089          .126        .091         -.105      .137       .488**      -.074        -.249       .160        1.00         .209 
 
Education         -.031          .133        -.005         -.151      .029       .046          .002         -.207       .090        .209         1.00 
__________________________________________________________________________________________________________________________ 
* p < .05, ** p < .01 
  
155
Appendix P 
Table 18 
Mean values of continuous predictor variables for decision aid group 
______________________________________________________________________________ 
Variable                                                       M (SD) 
______________________________________________________________________________ 
 
Age                                                              59.03 (9.14) 
 
Need for Cognition                                     58.33 (13.00) 
 
Monitoring/Blunting                                   4.00 (1.83) 
 
STAI                                                           35.33 (8.16) 
 
CES-D                                                         9.33 (7.61) 
 
______________________________________________________________________________ 
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Appendix Q 
Table 19 
Pearson Correlation Coefficients for Change in Knowledge, Reading Time, and Time until Decision 
____________________________________________________________________________________ 
                                 Change in Knowledge                  Reading Time                 Time until Decision 
____________________________________________________________________________________ 
 
Change in                             1.00                                      .386**                                       .033 
Knowledge                
 
Reading                                .386**                                   1.00                                          .345* 
Time             
 
Time until                             .033                                      .345*                                         1.00 
Decision                                  
_____________________________________________________________________________________ 
* p < .05, ** p < .01 
 
 
Table 20 
Mean values of reading time and time until decision for decision aid group 
______________________________________________________________________________ 
Variable                                                       M (SD) 
______________________________________________________________________________ 
 
Reading Time                                              16.43 (4.89) 
 
Time until Decision                                     14.00 (6.63) 
 
______________________________________________________________________________ 
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Appendix R 
 
Participant responses to Opinion of the Decision Aid Questionnaire 
 
What aspects of the Decision Aid were the most helpful in making your decision about 
treatment? 
Male 
1. benefits vs. risks 
2. description of each type of treatment and how they work and effects of each 
3. pros and cons, fact that final decision is mine, excellent explanations 
4. info and explanations 
5. Catherines situation 
6. no response 
7. comparison of pros and cons 
8. pros and cons with each treatment 
9. no response 
10. pros and cons 
11. benefits and risks 
12. frankness, side effects, each treatment discussed in same format 
13. benefits and risks of each treatment 
14. lists of treatments, pros and cons 
15. all the different situations 
Female 
16. pros and cons, made personal and realistic, think Id still ask doctor 
17. was helpful and informative, thought it was great 
18. lists of pros and cons 
19. explained what lymphoma is, what treatment options are available, and pros and cons 
20. risks and benefits 
21. none 
22. benefits/risks 
23. actual information about choices 
24. pros and personal importance to me 
25. what each treatment involved and side effects 
26. oncologists option 
27. describing approaches of treatments, what uses would be, side effects, outcomes 
28. pros and cons 
29. benefits and risks 
30. description of treatments, benefits and risks 
 
What aspects of the Decision Aid were the least helpful in making your decision about 
treatment? 
Male 
1. examples of therapy 
2. lists of authors and footnotes 
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3. found all helpful due to how uneducated I am on this subject 
4. research listings 
5. no comment 
6. possible consequences of choosing a treatment 
7. N/A 
8. felt I needed more information about the decision 
9. the clinical trial was left rather open-ended 
10. no response 
11. my inability to remember what each one was 
12. cant think of any 
13. not knowing what might be best for me 
14. list of materials used to gather info 
15. not knowing whats right 
Female 
16. each persons case is different so hard to say which treatment is best right now 
17. its still a tough decision 
18. would like to know more about exact treatment time, hospital stay time, possible 
remission time 
19. well-written, explained disease and treatments in layman terms, there was nothing that 
was not helpful 
20. background info 
21. none 
22. would have liked more information about survival time 
23. not knowing information about the choices 
24. all helpful so I cant really answer this question 
25. I think it was all helpful 
26. treatment already given 
27. no in-depth stud of the personal health and other factors that could contribute to the 
decision-making process 
28. no clue ahead of time what this was about 
29. probably discussion on lymphatic system 
30. anatomy and function of the lymphatic system 
 
 
